## BMJ Global Health

# Modelling the effect of infection prevention and control measures on rate of *Mycobacterium tuberculosis* transmission to clinic attendees in primary health clinics in South Africa

Nicky McCreesh <sup>(1)</sup>, <sup>1</sup> Aaron S Karat <sup>(2)</sup>, <sup>1,2</sup> Kathy Baisley, <sup>1</sup> Karin Diaconu, <sup>2</sup> Fiammetta Bozzani <sup>(2)</sup>, <sup>1</sup> Indira Govender, <sup>1,3</sup> Peter Beckwith, <sup>4</sup> Tom A Yates, <sup>5</sup> Arminder K Deol, <sup>1</sup> Rein M G J Houben <sup>(2)</sup>, <sup>1</sup> Karina Kielmann <sup>(2)</sup>, <sup>2</sup> Richard G White <sup>(2)</sup>, <sup>1</sup> Alison D Grant <sup>(2)</sup>, <sup>1,3,6</sup>

#### ABSTRACT

**To cite:** McCreesh N, Karat AS, Baisley K, *et al.* Modelling the effect of infection prevention and control measures on rate of *Mycobacterium tuberculosis* transmission to clinic attendees in primary health clinics in South Africa. *BMJ Global Health* 2021;**6**:e007124. doi:10.1136/ bmjgh-2021-007124

#### Handling editor Alberto L Garcia-Basteiro

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10. 1136/bmjgh-2021-007124).

RGW and ADG are joint senior authors.

Received 7 August 2021 Accepted 8 October 2021

#### Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Nicky McCreesh; nicky.mccreesh@lshtm.ac.uk **Background** Elevated rates of tuberculosis in healthcare workers demonstrate the high rate of *Mycobacterium tuberculosis (Mtb)* transmission in health facilities in highburden settings. In the context of a project taking a whole systems approach to tuberculosis infection prevention and control (IPC), we aimed to evaluate the potential impact of conventional and novel IPC measures on *Mtb* transmission to patients and other clinic attendees.

Methods An individual-based model of patient movements through clinics, ventilation in waiting areas. and Mtb transmission was developed, and parameterised using empirical data from eight clinics in two provinces in South Africa. Seven interventions-codeveloped with health professionals and policy-makers-were simulated: (1) queue management systems with outdoor waiting areas, (2) ultraviolet germicidal irradiation (UVGI) systems, (3) appointment systems, (4) opening windows and doors, (5) surgical mask wearing by clinic attendees, (6) simple clinic retrofits and (7) increased coverage of long antiretroviral therapy prescriptions and community medicine collection points through the Central Chronic Medicine Dispensing and Distribution (CCMDD) service. Results In the model, (1) outdoor waiting areas reduced the transmission to clinic attendees by 83% (IQR 76%-88%), (2) UVGI by 77% (IQR 64%-85%), (3) appointment systems by 62% (IQR 45%-75%), (4) opening windows and doors by 55% (IQR 25%-72%), (5) masks by 47% (IQR 42%-50%), (6) clinic retrofits by 45% (IQR 16%-64%) and (7) increasing the coverage of CCMDD by 22% (IQR 12%-32%).

**Conclusions** The majority of the interventions achieved median reductions in the rate of transmission to clinic attendees of at least 45%, meaning that a range of highly effective intervention options are available, that can be tailored to the local context. Measures that are not traditionally considered to be IPC interventions, such as appointment systems, may be as effective as more traditional IPC measures, such as mask wearing.

#### Key questions

#### What is already known?

- ► There are elevated rates of *Mycobacterium tuberculosis* (*Mtb*) transmission in healthcare facilities in high-burden settings.
- A range of infection prevention and control (IPC) measures exist, but estimates of their potential effects on transmission are limited.

#### What are the new findings?

- ► We estimate the potential effects of seven conventional and novel IPC interventions on *Mtb* transmission to patients in primary healthcare clinics in South Africa.
- The interventions are estimated to reduce the rate of transmission by 22%–83%, with six of the seven interventions achieving reductions of at least 45%.

#### What do the new findings imply?

- A range of highly effective intervention options are available, that can be tailored to the local context.
- Measures that are not traditionally considered to be IPC interventions, such as appointment systems, may be as effective as more traditional IPC measures, such as mask wearing.

#### INTRODUCTION

All else being equal, the risk of tuberculosis from transmission in primary healthcare (PHC) clinics is likely to be higher than in many other types of congregate settings, due to higher rates of clinic attendance both by people with infectious tuberculosis, and by people at high risk of progression to disease.<sup>1</sup> Evidence for high rates of *Mycobacterium tuberculosis* (*Mtb*) transmission in health facilities can be found in studies of infection or disease risk in healthcare workers, with a recent systematic review finding an incidence of tuberculosis in healthcare workers in high burden countries 2–12 times higher than in the general population.<sup>2</sup>

The challenge of high rates of Mtb transmission in healthcare facilities comes with opportunities for control. Compared with many other putative high transmission risk congregate settings such as bars<sup>3</sup> or public transport,<sup>4</sup> healthcare facilities should be relatively accessible settings for infection prevention and control (IPC) interventions. Two recent reviews, however, have identified a number of barriers to the successful implementation of IPC measures in healthcare facilities, including lengthy, ambiguous or unclear guidelines; overwork; lack of training; lack of space and/or equipment and concerns about patient stigmatisation.<sup>5</sup> <sup>6</sup> The Umoya omuhle ('good air' in isiZulu) project was designed to address these barriers, taking a multidisciplinary whole systems approach to understanding the drivers of *Mtb* transmission in PHC clinics in South Africa, and the individual and system constraints to implementing IPC measures.<sup>7</sup> The project combined quantitative and qualitative data collection, and used a system dynamics modelling approach<sup>8</sup> to identify potential IPC interventions. Interventions were selected that local policy-makers and health professionals, working at PHC and province levels (including PHC and district level healthcare workers), ranked highly in terms of both feasibility of implementation and perceived likely impact.9

To make informed and evidence-based decisions on the implementation of IPC measures in PHC clinics, it is necessary to know the likely effects of the interventions on transmission risk. Empirical data on intervention impact are limited however, and focus on risk to healthcare workers, and on hospital settings,<sup>10</sup> likely due to the difficulties in empirically evaluating changes in risk to patients and other clinic attendees. We therefore use mathematical modelling to fill this key information gap, using a model of patient movement through clinics and ventilation rates (informed by empirical data on both) to estimate the potential effects of the interventions on the rate of *Mtb* transmission to clinic attendees in PHC clinics in KwaZulu-Natal and Western Cape provinces, South Africa. In doing so, we provide information that is critical to policy-makers, to inform decisions on which intervention or interventions to implement in clinics.

#### **METHODS**

#### Clinic attendee movement data Collection

Clinic attendee movement data were collected on a single day per clinic, in six PHC clinics in KwaZulu-Natal province in February-March 2019, and five in Western Cape in May 2019 (with the exception of one clinic in KwaZulu-Natal, where data were collected on two separate days).<sup>11</sup> Briefly, all patients and other clinic attendees (people attending with or on the behalf of patients) arriving at the clinic or present at the clinic at the start of data collection were given a unique barcode. Research staff with barcode scanners were positioned at key points throughout the clinic, including the facility entrance(s), the filing window where patients registered and collected their medical record, the triage/vitals station where measurements such as blood pressure were taken, and doorways of waiting areas and some consultation rooms. Each time that a clinic attendee passed through a doorway or visited a station (eg, the filing window) their barcode was scanned, recording the time and the location. This allowed the attendees' movements through the clinic to be tracked. Basic demographic information and information on visit reasons were collected from all attendees. Clinic staff were also assigned barcodes, and their movements tracked. Table 1 shows the number of attendees recorded at each clinic, the clinic opening time and the time and number of attendees present at the start and end of data collection.

Table 1         Clinic information							
				Start of	data collection	End of d	lata collection
	Clinic ID number	Number of attendees*	Clinic opening time	Time	Attendees present†	Time	Attendees present†
KwaZulu-Natal	1	417	07:00	07:11	130 (31%)	14:19	129 (31%)
	2	171	07:00	07:54	37 (22%)	14:08	47 (27%)
	5	349	07:00	07:45	69 (20%)	14:19	89 (26%)
	6	377	07:30	08:27	63 (17%)	14:02	34 (9%)
Western Cape	8	69	07:30	07:49	2 (3%)	14:04	11 (16%)
	9	120	07:30	08:31	44 (37%)	14:06	38 (32%)
	11	308	07:00	07:37	157 (51%)	14:51	43 (14%)
	12	144	07:30	07:59	39 (27%)	14:03	17 (12%)

Clinic ID numbers correspond to numbers used in other papers from the Umoya omuhle project.

\*Number of patients and other clinic attendees included in the data collection.

†Number and proportion of all patients and other clinic attendees included in the data collection who were already present at the start of data collection, or still present at the end.

Full details of the data collection methods and results are given in Karat *et al.*<sup>11</sup>

#### Analysis

Data on clinic attendee movements were only collected from all main areas of the clinic in eight clinics, four in KwaZulu-Natal and four in Western Cape, and therefore only those clinics were considered in this work.

Attendees' movements through the clinic were simplified to four key stages/times: the time they arrived at the clinic, the time that they were first recorded at the filing window ('files'), the time that they were first recorded at the triage/vitals station ('vitals') and the time they left the clinic. All attendees were assumed to pass through each of the four stages, in order. These times were missing for many individuals, due to their barcode not being scanned, or their arrival or departure occurring outside the data collection period. Missing data on these times were imputed using multiple imputation (see online supplemental material for details). The times that attendees started consultations were also estimated, from the attendees' leaving times and data on mean consultation lengths.

Due to missing data on attendees' movements between waiting areas, attendees' waiting locations were also simplified, with each attendee assigned a single waiting area for each stage: waiting for files, waiting for vitals and waiting for any consultations (including the pharmacy). Waiting areas were assigned based on recorded barcode scans into and out of waiting areas, and knowledge of clinic space use (see online supplemental material for details).

In total, 40 baseline attendee datasets were created for each clinic, incorporating the uncertainty in the four times and three waiting locations.

#### Patient and public involvement

Methods used to collect and analyse patient flow data were developed through informal consultation with a range of stakeholders, including clinic managers and other healthcare workers and attendees at an Umoya omuhle workshop on patient flow and waiting times, which included patient representatives. The Umoya omuhle study was discussed with and approved by the Africa Health Research Institute's community advisory board prior to the finalisation of the protocol.

#### Ventilation and room size data

Data on ventilation rates were collected on 84 occasions from 57 rooms in 10 clinics in KwaZulu-Natal and Western Cape, using carbon dioxide  $(CO_2)$  release experiments and continuous  $CO_2$  concentration data, with the room doors and windows in typical in-use configurations ('usual conditions'). Room measurements were also made, and room volumes calculated. Ventilation rates, measured in air changes per hour (ACH), were calculated for each room. Details are given in Deol *et al.*<sup>12</sup>



**BMJ Global Health** 

**Figure 1** Example illustration of the movement of two hypothetical patients through a clinic in the model. The blue and green shadings indicate different waiting areas.

Data were also collected from 20 clinic rooms, with all windows and doors fully open ('maximum ventilation conditions'). The relative change in ACH in maximum ventilation conditions was calculated for each room, relative to the ACH in usual conditions in the same room on the same day.

#### Model

#### Clinic attendee movements

We developed an individual-based model that tracked the time at each stage for each clinic attendee (arrival, files, vitals and leaving), and the locations that they were waiting in between stages. Figure 1 illustrates the movement through the model for two hypothetical patients, and full details are given in the online supplemental material.

#### Transmission risk

Transmission risk was calculated using an approach based on the Wells-Riley equation<sup>13</sup>, and assuming no saturation of infection risk between model time steps. Results are presented as relative reductions in risk only, due to the large amounts of uncertainty that exist in quanta production rates.<sup>14</sup> The estimated mean number of quanta ('infectious doses')<sup>15</sup> in each waiting area of the clinic was tracked over time, assuming that 1% of adult patients<sup>16</sup> and 0.02% of child patients<sup>16–18</sup> had potentially infectious tuberculosis. Estimates of ventilation rates were used to determine the rate at which quanta were cleared from the room. Cumulative infection risk over time was tracked both for each individual attendee, and by room. Overall infection risk was calculated as the sum of infection risk for all simulated clinic attendees, over all time they spent in clinic waiting areas.

Full details of the model and model parameterisation are given in the online supplemental material.

#### Interventions

Seven potential IPC interventions had been identified through qualitative research and system dynamics modelling workshops conducted as part of the *Umoya omuhle* project.<sup>9</sup> They were implemented individually in the model as follows:

1. *Opening windows and doors*. Ensuring windows and doors in waiting areas are kept open at all times. This was implemented in the model through increased ACHs, with the relative increase in each waiting area and model run sampled from a distribution fitted to the empirical ventilation data.

- 2. *Simple clinic retrofits*. Retrofits are changes to the building to improve ventilation rates. This could include installing lattice brickwork or whirlybird fans. Due to the large amount of variation between clinic spaces in the types of building retrofits that would be suitable, and the lack of sufficient data on the effects of the retrofits on ventilation rates in different types of spaces, we did not model specific retrofits or packages of retrofits. Instead, we simulated an undefined package of retrofits that are sufficient to increase ACH to a minimum of 12 in all rooms, chosen in line with WHO guidelines.<sup>2 19</sup>
- 3. *UVGI systems*. We assume in this intervention that appropriate and well-maintained ultraviolet germicidal irradiation (UVGI) systems are installed in all indoor clinic waiting areas. This was implemented in the model through an additional quanta clearance rate, equivalent to a ventilation rate of 24 ACH (95% CI 9.9 to 62).<sup>20</sup>
- 4. Surgical mask wearing by clinic attendees. Based on discussions with healthcare workers and professionals active in the management of health services in the two provinces we worked in, as well as review of qualitative data collected, we determined that a scenario where 70% of attendees wear surgical masks 90% of the time was plausible. This was implemented in the model as 63% of attendees wearing masks 100% of the time, with the attendees who wear the masks chosen at random each model run. Masks were assumed to reduce the rate of quanta production by 75% (95% CI 56% to 85%),<sup>21</sup> and have no effect on rate of infection for the person wearing the mask.<sup>22</sup>
- 5. Increased CCMDD coverage. South Africa's Central Chronic Medicine Dispensing and Distribution (CCMDD) programme is designed to allow patients with stable chronic health conditions to collect their medicines from convenient locations, such as local pharmacies.<sup>23</sup> This means that they do not need to queue at clinics unnecessarily. The purpose of this intervention is to increase the coverage of CCMDD and similar programmes for eligible patients on antiretroviral therapy (ART), and to ensure that pick-up points do not require patients to queue at clinics. We assumed that 92% (95% CI 84% to 95%) of patients could have their ART appointments reduced to once every 6 months,<sup>24</sup> and that the remaining 8% of people need monthly ART appointments. This was implemented in the model through removing 31% (IQR) 22%-34%) of patients attending for HIV care, chosen at random each model run.
- 6. Queue management system with outdoor waiting areas. Empirical data show that clinic waiting areas are often crowded, and that in many clinics, patients wait in unsuitable areas such as corridors.<sup>11</sup> Conversations with clinic staff suggested that this is partly due to patient concerns that if they wait in other areas, they may not hear their name being called, and may miss their turn. This intervention therefore combines a large, covered outdoor waiting area with a queue management sys-

tem. We assumed that only 5–10 patients would be allowed to wait inside the clinic for each of the three stages, with the rest waiting in a large, covered, outdoor waiting area, with a very high ventilation rate of 52–70 ACH.<sup>25</sup>

7. Appointment system. In this intervention, we simulated an appointment system to reduce clinic overcrowding, through spacing out the arrival times of patients. As date-time appointment systems were already in place in some form in the Western Cape clinics on the day that the patient data were collected, we only modelled the appointment intervention in the KwaZulu-Natal clinics. We assumed that all patients aged <16 years and a proportion of patients with acute visit reasons would arrive at the clinic at the same time as in the baseline scenario, and be seen the same day. We assumed that all adult chronic patients, and a proportion of adult acute patients would be given appointments, with their arrival time spaced out between 9 am and 2 pm.

The CCMDD intervention reduces the number of patients, and the appointment system intervention changes the arrival times of some patients. Both these interventions may have consequences for the times that other patients are seen at each stage (files, vitals and consultations/leaving). The consequences are likely to vary by stage, and will vary depending on whether or not the stage is rate limiting. In other words, does the stage usually have the capacity to see patients as soon as they are ready, or are there usually queues? The model therefore contained two scheduling mechanism options per stage, which assume that the stage is or is not rate limiting.

Full details of the model and simulated interventions are given in the online supplemental material.

#### Model runs and uncertainty estimation

For each of the 40 patient datasets (incorporating the uncertainty in the times and waiting locations), 100 ventilation input sets were created, with the baseline ACH in each room varying between input sets. For each of the 4000 combinations, four different scheduling scenarios were simulated, assuming that the files and vitals stages are or are not rate limiting, in a two-by-two factorial design. Consultations/leaving was assumed to be a rate limiting stage in all the main model runs. This gave a total of 16 000 model runs for each clinic and intervention.

In addition to this, as a sensitivity analysis, an additional 16 000 model runs were done for each clinic and intervention, where it was assumed that consultations were not a rate limiting stage.

#### RESULTS

# Effect of the interventions on the relative rate of transmission to patients

Figure 2 shows the estimated reduction in the rate of *Mtb* transmission to patients in each of the intervention scenarios, compared with the baseline scenario, overall and by province. Overall, in the model, opening windows



**Figure 2** Estimated reduction in the rate of *Mycobacterium tuberculosis* transmission to patients in clinics, by province and intervention. The central line indicates the median, the box range the IQR, the whiskers the most extreme value within 1.5 \* IQR from the box, and the points outlying values. In the queue management intervention in KwaZulu-Natal, 1.3% of points were below –20%, with a minimum of –162%. In the appointment system intervention in KwaZulu-Natal, 1.3% of points were below –20%, with a minimum of –83%. These points are not shown on the graph. The appointment system intervention was not modelled in Western Cape, due to the presence of existing appointment systems. CCMDD, Central Chronic Medicine Dispensing and Distribution; UVGI, ultraviolet germicidal irradiation.

and doors reduced the transmission rate by 55% (IQR 25%-72%), clinic retrofits by 45% (IQR 16%-64%), installing UVGI by 77% (IQR 64%-85%), surgical mask

## **BMJ Global Health**

wearing by patients by 47% (IQR 42%–50%), increasing the coverage of CCMDD by 22% (IQR 12%–32%) and a queue management system plus outdoor waiting area by 83% (IQR 76%–88%). In the KwaZulu-Natal clinics, implementing an appointment system in the model reduced the transmission rate by 62% (IQR 45%–75%).

There was little variation in estimated impact by province, with the exception of increasing the coverage of CCMDD, where reductions in the transmission rate were higher in KwaZulu-Natal clinics (28% IQR 20%–39%) than in Western Cape clinics (15% IQR 8%–24%), reflecting the higher prevalence of HIV and higher ART coverage in KwaZulu-Natal.

Figure 3 shows the number of patients in the clinic 1 over time in the baseline scenario, then with the appointment system and the CCMDD intervention. The lower panels show the mean rate of transmission to each patient in the clinic over time in all scenarios. Similar figures for the other clinics are in the online supplemental material.

#### Sensitivity analyses

Simulating consultations as a non-rate limiting stage reduced the estimated reduction in the rate of transmission from 22% (IQR 12%–32%) to 15% (IQR 8.7%–23%) in the CCMDD scale-up intervention, and from 62% (IQR 45%–75%) to 24% (IQR 13%–47%) in the appointments intervention (online supplemental figure S3).

#### DISCUSSION

In this paper, we estimated the potential effects of seven interventions on the rate of Mtb transmission to patients



**Figure 3** Number of patients in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each patient in the clinic over time in all scenarios, for clinic 1. The black line shows the median result, the dark red band the IQR and the light red band the 95% plausible range. For interventions where a plot of the number of patients over time is not shown, the intervention has no effect on patient numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. Figures for the other clinics are shown in the supplemental material. CCMDD, Central Chronic Medicine Dispensing and Distribution; UVGI, ultraviolet germicidal irradiation.

and other clinic attendees in PHC clinics in two provinces in South Africa. A queue management system with outdoor waiting areas and installing UVGI systems were identified as the most effective interventions, reducing the rate of transmission by an estimated 83% and 77%, respectively. The majority of interventions resulted in substantial reductions in the transmission rate however, demonstrating that a range of highly effective IPC measures exist. This includes appointment systems, which are not traditionally considered as IPC measures. This highlights the benefits of broadening our views of IPC and expanding our view of the population to be protected beyond healthcare workers, to also include patients and other clinic attendees.

Many of the interventions could be implemented in different ways in practice, increasing or decreasing their effects. For example, installing a more extensive package of retrofits, or taking measures to achieve a higher level of mask wearing. Combining interventions will also increase impact, although returns will diminish with multiple interventions. The COVID-19 pandemic may also have led to changes in the way that PHC clinics operate, some of which may last beyond the end of the epidemic. For example, the acceptability to clinic attendees of mask wearing may increase, increasing the coverage that can be achieved. When interpreting the results, consideration should therefore be given to any differences in the way that we implemented the intervention in the model, and the way that they would be implemented in a specific context. Nevertheless, our results provide a useful baseline estimate of the impacts and relative impacts of the different interventions.

The choice of IPC intervention(s) to implement at the clinic level, or to recommend at a district or provincial level, will necessarily also be guided by other factors. The costs of implementing and maintaining the different interventions will be a key factor, and is being explored in further work as part of the Umoya omuhle project. Guided by a whole systems approach, we have comprehensively costed the interventions proposed by also considering how to overcome potential system and practical barriers to implementation. The ease and practicality of implementation is also an important consideration, and will vary by clinic. For instance, is there sufficient space to install an outdoor waiting area? And is the climate suitable for interventions that increase natural ventilation rates? The systems dynamics modelling work conducted to identify the interventions simulated here also aimed to identify the mechanisms necessary to achieve the interventions. For instance, for ensuring an effective queue management programme, mechanisms such as community and health service staff consultation and creation of covered outdoor waiting areas were discussed.<sup>9</sup>

Some of the interventions have additional benefits to patients. Improving the coverage of CCMDD may be beneficial to patients stable on ART, reducing the amount of time they spend queuing at clinics and the financial cost to patients. An appointment system should also reduce the time spent at clinics for the majority of patients. The effect of the interventions on risk of transmission to healthcare workers and other clinic staff should also be considered. All the interventions described here will reduce risk to all staff situated in waiting areas, such as security guards and clerks in some clinics. Many of the interventions will also reduce risk to staff in consultation rooms, provided that the interventions are also implemented in those spaces. Interventions that reduce risk by reducing overcrowding in waiting areas (appointment systems, CCMDD scale-up and outdoor waiting areas) will have little effect on risk for staff based in consultation rooms however.

Finally, we estimate the effect of the interventions on an airborne infection, M. tuberculosis. The relative effects of the different interventions on other infections that spread primarily through airborne transmission, such as measles and chickenpox, are likely to be similar, although the concentration of these infections in children rather than adults may alter the effects slightly. The effects will differ, however, for infections where droplet or fomite transmission may play a larger role, such as SARS-CoV-2 and influenza. Fully exploring the impact on these infections is beyond the scope of this paper, however, as a rough guide, interventions that act through reducing patient concentrations (CCMDD and appointments systems) or reducing the release of pathogens (masks) will have a greater effect on these infections than interventions that act through improving ventilation (opening windows and doors, clinic retrofits, outdoor waiting areas) or air disinfection (UVGI).

There are a number of limitations to this work. First, empirical data on the flow of clinic attendees through clinics were only available for 1 day per clinic, meaning that we cannot disentangle variation between the simulated clinics in the intervention effects that arises from day-to-day variation within the clinic from that which arises from variation between clinics. For this reason, the results are presented by province only in the main results figure, rather than by clinic. Additional empirical data (both on patient movements and ventilation rates in waiting areas), and simulated clinic days, would also increase the confidence that our results incorporate the full range of variation between clinics and clinic days. Similarly, data from additional clinics would increase the generalisability of our results.

Second, there were large amounts of missing data in the clinic attendee movement datasets. Missing data were imputed using multiple imputation, and the effects of the uncertainties in patient times and waiting locations were reflected in the size of the uncertainty bounds around the results. Multiple imputation relies on the assumption that the data are missing at random however, which may not be true for our data sets. We also assume that all clinic attendees visited both files and vitals in turn, and that all attendees waited in a single location per stage, which may not have been the case for all attendees. For these reasons, our results for each clinic day should be considered to be indicative of the interventions' effects in the clinic, rather than a definitive estimate of the effects of the interventions on each specific clinic day. We may also have missed a number of attendees entirely if they left before the start of data collection, or arrived after the end. The effects of this are likely to have been minimal however, as attendees leaving before the start of data collection could only have spent a small amount of time at the clinic, and attendee numbers were relatively small and fell rapidly after the end of data collection.<sup>11</sup>

Due to the large amounts of missing data in the clinic attendee movement data sets, we were also unable to simulate in any detail the process of queuing for consultations with nurses and doctors, and for the pharmacy. Instead, we simulated a single queue for consultations, using data on clinic leaving times. This is unlikely to have had a substantial effect on the estimates for the majority of interventions, but may mean that we underestimated or overestimated the effects of the appointment systems and CCMDD coverage scale-up interventions. The large amounts of missing data also prevented us from considering the pathways of people who were accompanying patients or attending on the behalf of someone else separately from the pathways of patients, and all clinic attendees are treated as 'patients' in the model. This is unlikely to have had a large effect on the results, as the people accompanying patients are likely to have spent the majority of the time in the same waiting areas as the patients they were accompanying.

Our results will also have been influenced by assumptions made in the parameterisation of the interventions. For instance, we assume that surgical masks offer no direct protection against infection to the wearer of masks, with the reduction in risk coming from mask wearing by infectious people only.<sup>22</sup> If surgical masks also provide some direct protection against infection, then we may have underestimated the effects of the mask wearing intervention.

In a small proportion of runs, the simulated interventions increased the rate of transmission. In the CCMDD and appointment interventions, this occurred through rearrangements in patient pathways making waiting times for some patients higher, or concentrating patients in higher risk waiting areas. These rare outliers reflect day-to-day variation, rather than highlighting a real potential for the interventions to consistently increase risk. For the queue management intervention, increased rates of transmission occurred in model runs where high sampled baseline ventilation rates in waiting areas coincided with a low sampled ventilation rate in the outdoor waiting area in the intervention scenario. In reality, ventilation rates in different areas will be correlated, with both influenced by the same factors such as wind speed,  $^{26}$  and it is therefore likely that the outlier runs overestimate the true uncertainty.

#### CONCLUSIONS

To conclude, we show the estimated effects on the rate of *Mtb* transmission to clinic attendees of a range of IPC infections. Median reductions range from 83% for a queue management system with outdoor waiting areas, to 22% from scaling up coverage of CCMDD among ART patients. The majority of the interventions (6/7) achieve reductions of at least 45%, meaning that a range of highly effective conventional and novel IPC intervention options are available, that can be tailored to the local context.

#### Author affiliations

<sup>1</sup>TB Centre, London School of Hygiene and Tropical Medicine, London, UK
<sup>2</sup>Institute for Global Health & Development, Queen Margaret University Edinburgh, Musselburgh, UK

<sup>3</sup>Africa Health Research Institute, School of Laboratory Medicine & Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa

<sup>4</sup>Department of Medicine, University of Cape Town, Rondebosch, South Africa
<sup>5</sup>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK

 $^{\rm 6}\mbox{School}$  of Public Health, University of the Witwatersrand, Johannesburg, South Africa

Twitter Fiammetta Bozzani @piccolafiamma and Richard G White @richardwhite321

**Acknowledgements** We would like to thank the managers, staff, patients and visitors at participating clinics and all of the Umoya omuhle project team involved in the data collection. Full details are given in the supporting material.

**Contributors** NM conceived, designed and conducted the modelling work and wrote the paper. ASK, NM and ADG designed the patient movement data collection, and ASK and IG conducted the data collection. KB conducted the multiple imputation. PB, TAY and IG collected the ventilation data, and PB, TAY and AKD analysed it. KD designed and led the system dynamics modelling to inform intervention choice and design, with contributions from ASK, KK, ADG. ADG, KK, NM, TAY, RW and RMGJH obtained funding. NM is responsible for the overall content as guarantor. All authors read, commented on and approved the paper.

**Funding** The support of the Economic and Social Research Council (UK) is gratefully acknowledged. The project is partly funded by the Antimicrobial Resistance Cross Council Initiative supported by the seven research councils in partnership with other funders including support from the GCRF. Grant reference: ES/P008011/1. NM is additionally funded the Wellcome Trust (218261/Z/19/Z). RGW is funded by the Wellcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01), EDTCP (RIA208D-2505B), UK MRC (CCF17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (OPP1084276, OPP1135288 & INV-001754) and the WHO (2020/985800-0). TAY is funded via an NIHR Academic Clinical Fellowship. RMGHJ is funded by ERC (action number 757699).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The clinic attendee movement and ventilation data collection received ethical approval from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (ref. BE082/18), the Human Research Ethics Committee of the Faculty of Health Sciences of the University of Cape Town (ref. 165/2018), the Research Ethics Committee of Queen Margaret University (ref. REP 0233) and the Observational/Interventions Research Ethics Committee of the London School of Hygiene & Tropical Medicine (ref. 14872).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. Data are available upon reasonable request. Model code is available from https://github.com/NickyMcC/WithinClinics. The patient flow datasets will be made available from https://datacompass.lshtm.ac.uk/.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those

### **BMJ Global Health**

of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

#### ORCID iDs

Nicky McCreesh http://orcid.org/0000-0003-1409-8531 Aaron S Karat http://orcid.org/0000-0001-9643-664X Fiammetta Bozzani http://orcid.org/0000-0002-9518-6885 Rein M G J Houben http://orcid.org/0000-0003-4132-7467 Karina Kielmann http://orcid.org/0000-0001-5519-1658 Richard G White http://orcid.org/0000-0003-4410-6635 Alison D Grant http://orcid.org/0000-0002-2437-5195

#### REFERENCES

- 1 McCreesh N, Grant AD, Yates TA, et al. Tuberculosis from transmission in clinics in high HIV settings may be far higher than contact data suggest. Int J Tuberc Lung Dis 2020;24:403–8.
- 2 World Health Organization. Who guidelines on tuberculosis infection prevention and control: 2019 update. World Health Organization, 2019.
- 3 Murray EJ, Marais BJ, Mans G, *et al.* A multidisciplinary method to map potential tuberculosis transmission 'hot spots' in high-burden communities. *Int J Tuberc Lung Dis* 2009;13:767–74.
- 4 Andrews JR, Morrow C, Wood R. Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa. *Am J Epidemiol* 2013;177:556–61.
- 5 Houghton C, Meskell P, Delaney H, *et al.* Barriers and facilitators to healthcare workers' adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: a rapid qualitative evidence synthesis. *Cochrane Database Syst Rev* 2020;4:CD013582.
- 6 Tan C, Kallon II, Colvin CJ, et al. Barriers and facilitators of tuberculosis infection prevention and control in low- and middleincome countries from the perspective of healthcare workers: a systematic review. PLoS One 2020;15:e0241039.
- 7 Kielmann K, Karat AS, Zwama G, *et al.* Tuberculosis infection prevention and control: why we need a whole systems approach. *Infectious Diseases of Poverty* 2020;9:1–4.
- 8 Chang AY, Ogbuoji O, Atun R, et al. Dynamic modeling approaches to characterize the functioning of health systems: a systematic review of the literature. Soc Sci Med 2017;194:160–7.

- 9 Diaconu K, Parkhurst J. Health systems webinar: Applying a 'whole systems' approach to infection prevention & control in primary health care clinics in South Africa. Using System Dynamics Modelling in Umoya omuhle, 2021. Available: https://www.lshtm.ac.uk/research/ centres-projects-groups/uo#events
- 10 Karat AS, Gregg M, Barton HE, et al. Evidence for the use of triage, respiratory isolation, and effective treatment to reduce the transmission of Mycobacterium tuberculosis in healthcare settings: a systematic review. *Clinical Infectious Diseases* 2020;390:155–72.
- 11 Karat AS, McCreesh N, Baisley K. Waiting times, occupancy density, and patient flow in South African primary health clinics: implications for infection prevention and control. *MedRxiv*2021:2021.07.21.21260806.
- 12 Deol AK, Scarponi D, Beckwith P, et al. Estimating ventilation rates in rooms with varying occupancy levels: relevance for reducing transmission risk of airborne pathogens. *PLoS One* 2021;16:e0253096.
- Riley EC, Murphy G, Riley RL. Airborne spread of measles in a suburban elementary school. *Am J Epidemiol* 1978;107:421–32.
   Beggs CB, Noakes CJ, Sleigh PA, *et al.* The transmission of
- 14 Beggs CB, Noakes CJ, Sleigh PA, et al. The transmission of tuberculosis in confined spaces: an analytical review of alternative epidemiological models. Int J Tuberc Lung Dis 2003;7:1015–26.
- 15 Wells WF. Airborne contagion and air hygiene: an ecological study of droplet infections. *JAMA* 1955;159:90.
- 16 Govender I, Karat AS, Baisley K. Prevalence of M. tuberculosis in sputum among clinic attendees compared with the surrounding community in rural South Africa: implications for finding the missing millions. 51st Union world conference on lung health 2020.
- 17 Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, et al. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. *BMC Infect Dis* 2016;16:282–82.
- 18 World Health Organization. Global tuberculosis report 2019. Geneva, Switzerland: World Health Organization, 2019.
- 19 Chartier Y, Pessoa-Silva C. Natural ventilation for infection control in health-care settings. World Health Organization, 2009.
- 20 Mphaphlele M, Dharmadhikari AS, Jensen PA, *et al.* Institutional tuberculosis transmission. controlled trial of upper room ultraviolet air disinfection: a basis for new dosing guidelines. *Am J Respir Crit Care Med* 2015;192:477–84.
- 21 Dharmadhikari AS, Mphahlele M, Stoltz A, *et al*. Surgical face masks worn by patients with multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 2012;185:1104–9.
- 22 MacIntyre CR, Chughtai AA. Facemasks for the prevention of infection in healthcare and community settings. *BMJ* 2015;350:h694.
- 23 Health Systems Trust. The CCMDD story, 2019.
- 24 Hst indicator tool, 2020. Available: https://indicators.hst.org.za/ [Accessed 7 Apr 2020].
- 25 Escombe AR, Ticona E, Chávez-Pérez V, et al. Improving natural ventilation in hospital waiting and consulting rooms to reduce nosocomial tuberculosis transmission risk in a low resource setting. BMC Infect Dis 2019;19:88.
- 26 Escombe AR, Oeser CC, Gilman RH, et al. Natural ventilation for the prevention of airborne contagion. *PLoS Med* 2007;4:e68.

## Supplemental material - Modelling the effect of infection prevention and control

## measures on rate of Mycobacterium tuberculosis transmission to clinic attendees in

## primary health clinics in South Africa

## Contents

	Supplem	nental methods	3
1.1	1 Imp	putation	3
	1.1.1	Times	3
	1.1.2	Locations	6
1.2	2 Ver	ntilation data	9
1.3	3 Mo	odel overview	10
1.4	4 Key	у	11
1.5	5 Atte	tendee input file	11
1.6	5 Mo	ovement through clinics	12
	1.6.1	Scheduling mechanism – rate limiting stages	13
	1.6.2	Scheduling mechanism – non-rate limiting stages	13
	1.6.3	Attendee waiting areas	
			14
1.7	7 Ind	dividual characteristics	14 14
1.7 1.8	7 Ind 3 Roc	dividual characteristics	14 14 15
1.7 1.8 1.9	7 Ind 3 Roc 9 Infe	dividual characteristics	14 14 15 15
1.7 1.8 1.9 1.1	7 Ind 3 Roc 9 Infe 10 Inte	dividual characteristics	14 14 15 15 16
1.7 1.8 1.9 1.1	7 Ind 3 Roc 9 Infe 10 Inte 1.10.1	dividual characteristics	14 14 15 15 16 16

	1.10	).3	UVGI systems				
	1.10	).4	Surgical masks wearing by clinic attendees				
	1.10	).5	Increased CCMDD coverage				
	1.10	0.6	Queue management system and outside waiting areas21				
	1.10	).7	Appointment systems				
	1.11	Inpu	it parameter values				
2	Sup	plem	ental results				
	2.1	Sens	sitivity analysis				
	2.2	Inte	rvention impact by clinic				
	2.3	Attendee numbers and rate of transmission over time29					
	2.4	Med	dian clinic visit durations				
3	Sup	plem	ental acknowledgements				
4	Refe	erenc	es				

# 1 Supplemental methods

## 1.1 Imputation

## 1.1.1 Times

Four key times were identified in the pathways that each clinic attendee took through the clinic:

- Arrival time. The time that they first arrived at the clinic. For attendees who arrived after the start of data collection, this was assumed to be the time that their barcode was first scanned. The arrival time was set to missing if the attendee was already present in the clinic before the start of data collection, or if the first time their barcode was scanned was not at a clinic entrance (an external door or compound gate).
- Files time. The time that the attendee obtained their patient file from the clinic reception desk. This was assumed to be the time that their barcode was first scanned at files, provided that it occurred before the first time that they were scanned at vitals or at a consultation room. The time was set to missing if they never scanned at files, or if they scanned at vitals or a consultation room before first scanning at files.
- Vitals time. The time that the attendee has their blood pressure, heart rate, and respiratory rate measured.
   This was assumed to be the time that their barcode was first scanned at vitals, provided that it occurred before the first time that they were scanned at a consultation room. The time was set to missing if they never scanned at vitals, or if they scanned at a consultation room before first scanning at vitals.
- Leave time. The time that the attendee left the clinic. This was assumed to have occurred at the final time that they scanned their barcode, provided it occurred at a clinic exit point (an external door or compound gate). The leaving time was set to missing for attendees who were still at the clinic at the end of data collection, or if their barcode was never scanned at an exit point.

In a small number of cases, times at files and/or vitals may be missing not because the attendee did not scan their barcode, but because the attendee did not complete that stage. For instance, some attendees who were at the clinic to collect medicine only may have skipped one or both stages. In many clinics, patients on TB treatment can also skip the files and vitals stages. In all eight clinics however, the majority of patients are required to pass through both files and vitals, regardless of their visit reason.

Table S1 shows the number and proportion of attendees with known and missing data for each stage.

				Arrival			Files		Vitals		Leaving		
	Clinic	Clinic	Number	Known	Missing	Missing	Known	Missing	Known	Missing	Known	Missing	Missing
		closing	of		(arrived							(left	
		time	attendees		early <sup>1</sup> )							late²)	
KwaZulu-	1	19:00	417	269	130	18 (4%)	66 (16%)	351	34 (8%)	383	248	129	40 (10%)
Natal				(65%)	(31%)			(84%)		(92%)	(59%)	(31%)	
	2	17:00	171	130	37 (22%)	4 (2%)	62 (36%)	109	66 (39%)	105	121	47 (27%)	3 (2%)
				(76%)				(64%)		(61%)	(71%)		
	5	16:30	349	257	69 (20%)	23 (7%)	14 (4%)	335	38 (11%)	311	247	89 (26%)	13 (4%)
				(74%)				(96%)		(89%)	(71%)		
	6	17:00	377	128	63 (17%)	186	99 (26%)	278	109	268	174	34 (9%)	169
				(34%)		(49%)		(74%)	(29%)	(71%)	(46%)		(45%)
Western	8	16:30	69	65 (94%)	2 (3%)	2 (3%)	35 (51%)	34 (49%)	23 (33%)	46 (67%)	55 (80%)	11 (16%)	3 (4%)
Cape	9	16:30	120	56 (47%)	44 (37%)	20 (17%)	34 (28%)	86 (72%)	40 (33%)	80 (67%)	54 (45%)	38 (32%)	28 (23%)
	11	16:30	308	111	157	40 (13%)	32 (10%)	276	24 (8%)	284	176	43 (14%)	89 (29%)
				(36%)	(51%)			(90%)		(92%)	(57%)		
	12	16:30	144	94 (65%)	39 (27%)	11 (8%)	39 (27%)	105	66 (46%)	78 (54%)	121	17 (12%)	6 (4%)
								(73%)			(84%)		

Table S1. The number and proportion of attendees with known and missing data for each stage, and clinic closing times <sup>1</sup>The person arrived before the start of data

collection. <sup>2</sup>The person left after the end of data collection

BMJ Global Health

Missing times were imputed as interval-censored values, with lower and upper bounds of when the event would have occurred, using a sequential approach. Firstly, arrival times at the clinic were multiply-imputed using 20 imputations. For attendees who arrived before the start of data collection, the lower and upper limits of the time of arrival were set to the clinic opening time and the start of data collection, respectively. For those who arrived after the start, the lower limit was set as the start of data collection, and the upper limit was the time that the attendee was first scanned. Secondly, the time at files was imputed, using the imputed arrival time as the lower bound of the interval and time at vitals (if observed) as the upper limit. If time at vitals was not observed, the upper bound was set to the earliest of the maximum time from arrival to files observed in that clinic, the time of leaving (if observed), end of data collection (if not there at end) or close of clinic (if there at end). Next, the time at vitals was imputed, using the imputed time at files as the lower bound of the interval, and the setting the upper bound to the earliest of the maximum time from files to vitals observed in that clinic, the time of leaving (if observed), end of data collection (if not there at end) or close of clinic (if there at end). Finally, the time of leaving the clinic was imputed, using the imputed time at vitals as the lower bound, and setting the upper bound to the earliest of the maximum time from vitals to leaving observed in that clinic, end of data collection (if not there at end) or close of clinic (if there at end).

Age, sex, clinic, reason for visit, whether there at start/end, and whether the attendee was first scanned in the morning (before 10am) were included in the imputation model. Two sets of 20 imputations were generated. In one, separate lower and upper limits were used for the morning and afternoon visits. This was done as there was some evidence in the empirical data that waiting times were shorter in the afternoons. In the second, the same lower and upper limits were used for all attendees.

For each attendee and imputation, an estimated time at consultations was generated. This was not designed to be an accurate estimate of the exact time that they started any particular consultation,

but instead was used to ensure that the time that attendees spent in waiting areas between vitals and leaving the clinic was not over-estimated. Observations in clinics suggested a mean time per consultation of seven minutes. We assumed that patients have an average of 1.5 consultations per visit, giving a mean length of time spent in consultations of 10.5 minutes. We also assumed that the majority of patients would need a minimum of 3 minutes between starting vitals and starting their first consultation. Finally, the estimated time starting consultations, 'consultation time', could not occur after 'leave time'. The estimated consultation time was therefore set to the latest of 1) attendees leave time – 10.5 minutes, 2) vitals time + 3 minutes, 3) leave time.

The files and vitals stages only take a short amount of time per patient, and in many clinics the patient remains in the files waiting area while their file is being retrieved. The time not spent in the waiting area for files and vitals is therefore considered to be negligible, and is not subtracted from the patients' waiting times in the model.

#### 1.1.2 Locations

We assume that each attendee waits in a single location for each stage of their clinic pathway. That is:

- Between arrival time and files time
- Between files time and vitals time
- Between vitals time and consultation time

Based on observation of the organisation of care and patient flow at each clinic, each stage was assigned a certain area or areas in which individuals would wait to be seen. For each individual, waiting locations for each stage were determined in three steps.

- 1. For individuals who had a recorded visit to a specific stage:
  - a. The location recorded immediately before the stage was used as the most likely waiting location if it was one of the waiting areas associated with that stage.

b. For stages with only one associated waiting location, individuals who had a recorded visit to a particular stage, but whose immediate previous location was not the waiting area for that stage, were nevertheless listed as having waited in that area, as it was considered likely that their entry and exit to that waiting area had been missed during data collection. For stages with more than one waiting location, individuals were randomised to one of the areas using the method described in point 3 below.

- c. For individuals who visited more than one consultation room, the first consultation room visited and associated waiting area were used.
- Individuals without a recorded visit to a specific stage (any of filing, vitals, or consultation) were assigned waiting locations based on the organisation of care at the clinic.
  - a. In clinics with a single filing and/or vitals stage, and where that stage had only one associated waiting area, all individuals were listed as having waited in the associated waiting area for a particular service. In clinics where a stage had more than one waiting area, individuals were randomised as described below.
  - b. In clinics with more than one filing and/or vitals stages (e.g., clinics with separate streams for 'acute' and 'chronic' patients), individuals were first categorised by stream, based on the reported reason for their visit and by the consultation room they had attended (if recorded). Once again, if a stage had only one associated waiting area (e.g., 'acute vitals'), all individuals in the appropriate stream (e.g., the 'acute' stream) were listed as having waited in that area. If a stage had more than one associated waiting area, individuals were randomised as described below.

3. After the completion of steps 1 and 2, any individuals without recorded waiting locations for any of the three stages were assigned at random to a waiting area associated with that stage. For each stage, the proportions of individuals to be assigned to each associated waiting areas was calculated using the assignments made in steps 1 and 2 above. The remaining individuals were then randomised to the associated waiting areas in the same proportions

A total of 20 attendee waiting location datasets were created for each clinic, incorporating the uncertainty in waiting locations.

The numbers and proportions of attendees with uncertain waiting locations (separated by waiting locations assigned by high probability [step 2, above] and by randomisation [step 3]) are shown in Table S2.

				Number of a	ttendees with	uncertain	waiting locati	on†, n (%)	
Province	Clinic	Number of	Number of	Files		Vitals		Consultations	
		attendees	waiting areas*	High probability	Randomised	High probability	Randomised	High probability	Randomised
KwaZulu-	1	417	2	92 (22)	171 (41)	113 (27)	140 (33)	111 (26)	196 (47)
Natal	2	171	4	0	107 (63)	0	89 (52)	0	83 (49)
	5	349	4	142 (41)	183 (52)	290 (83)	0	190 (54)	98 (28)
	6	377	4	268 (71)	0	257 (68)	0	172 (45)	60 (16)
Western	8	69	2	15 (22)	0	34 (49)	0	25 (36)	0
Cape	9	120	2	50 (42)	0	59 (49)	0	60 (50)	0
	11	308	5	275 (89)	0	281 (91)	0	295 (96)	0
	12	144	2	78 (54)	0	61 (42)	0	11 (7.6)	111 (77)

#### Table S2. The numbers and proportions of attendees with uncertain waiting locations, by clinic

and stage. \*includes informal waiting areas such as corridors. Informal and formal outdoor waiting areas are not included in this number. +'Uncertainty' separated into those to whom waiting location was assigned based on high probability (step 2 in text) or randomisation (step 3)

## 1.2 Ventilation data

Empirical data on air changes per hour (ACH) were available from a series of experiments conducted in a range of different rooms in the clinics<sup>1</sup>. Results from a small number of repeat experiments in the same rooms on different days showed that there were large amounts of variation in ventilation rates in the same room between different days. Estimated ACH were available from 84 experiments in 57 rooms (33 experiments in consultation rooms, and 51 in waiting areas) with a typical in-use number of windows and doors open or closed. There was little difference between estimated ACH between consultation rooms and waiting areas (mean 13.1 95% CI 8.2-18.0 and 18.5 95% CI 12.6-24.4, p=0.2), and therefore data from both types of area were used. An exponential distribution was fitted to the estimated rates (Figure 1), and simulated rates in each room were sampled from the distribution for each model run. Estimated air change rates per hour were similar between the data (mean 16.4, median 9.5, IQR 4.3-21.2) and the modelled distribution (mean 15.5, median 9.8, IQR 4.1-23.4).



# Figure S1. Empirical data on air changes per hour (ACH), and distribution used to generate ACH values in the model

#### 1.3 Model overview

The model was an individual-based model that tracks the movements of attendees through clinics, and *Mycobacterium tuberculosis* infection risk in clinic waiting areas over time, by area and by individual.

In the model, four key (clock) times control each attendee's movement through the clinic, through four corresponding stages: the time they arrive at the clinic, the time they collect their patient file ('files'), the time that their basic measurements are taken ('vitals'), and the time that they start consultations. It is assumed that they leave the clinic immediately after ending consultations, and spend negligible further time in waiting areas. Simulated attendees also each have an assigned waiting area where they wait between each stage (between arrival and files, between files and vitals, and between vitals and consultations). The four key times and three locations were determined, imputed and/or estimated for each attendee, and the complete dataset was used as input to the model. The simulated times and waiting locations remain unchanged in the model from those in the input files, in the baseline scenario and the majority of the intervention scenarios. In the appointment system and CCMDD interventions, the times are changed in the model, and in the queue management system, the waiting locations are changed.

The number of quanta in each waiting area is tracked over time. It is assumed that there is a prevalence of pulmonary tuberculosis among adult and child attendees of 1.0% and  $0.016\%^{2-4}$  respectively, and that attendees with pulmonary tuberculosis have a mean rate of quanta production of 1.25 per hour<sup>5</sup>. We implement this in the model by giving each adult and child a rate of quanta production of 8.9 x 10<sup>-3</sup> and 1.42 x 10<sup>-4</sup> per hour respectively.

Movement of clinic attendees was scheduled in the model using continuous time. Updating of quanta in waiting areas and individual's risks was scheduled on a time step, at intervals of *quanta\_rate\_ts*.

#### 1.4 Key

Model parameter names are written in *italics*, with colour indicating whether the parameter is an input parameter, a parameter with a global model-wide value, calculated from input parameter(s);or an individual-level parameter, which can take a different value for each simulated person, for each simulated waiting area, or for each simulated stage.

### 1.5 Attendee input file

Each model run for each clinic required an attendee input file, which had a row for each attendee, with the following information:

- 1. The attendee id
- The arrival time to be simulated for the attendee (equal to the imputed arrival time for all scenarios except the appointments intervention) (*arrival\_time*)
- The gap in the imputed data between the time they start a stage and the time that the next attendee starts the stage, for each stage (*duration\_files, duration\_vitals, duration\_cons*)
- 4. The gap in the imputed data between each of their own stages (*gap\_files, gap\_vitals*,

gap\_cons

5. The waiting location for each stage (*files\_queue\_location*, *vitals\_queue\_location*,

#### cons\_queue\_location)

Each attendee input file contained the same number of attendees for each clinic, with the exception of input files for the CCMDD intervention, where a proportion of attendees were removed (see section 'intervention scenarios'). The gaps between attendees in the input file (*duration\_files*, *duration\_vitals*, and *duration\_cons*) were not affected by the removal of attendees.

#### 1.6 Movement through clinics

All attendees enter the clinic at *arrival\_time*, and set their location to *files\_queue\_location* (with the exception of the queue management intervention-see Attendee waiting areas). The way that the movement through the other three stages (files, vitals, and consultations) is implemented in the model – the scheduling mechanism – depends on whether the stage is set to be rate limiting or not, for that particular model run. In practice, whether stages are set to be rate limiting or not has no effect on model output for the baseline scenario, or for the majority of intervention scenarios, as in both cases the scheduling mechanisms result in the simulated times at which attendees reach each stage being exactly equal to the corresponding times in the attendee input file. The choice of scheduling mechanism for each stage only effects the results when the number of attendees are changed (CCMDD intervention), or attendee arrival times are changes (appointment systems).

Observations in the clinics suggested that the consultations stage was rate limiting for the majority of patients, with patients queueing for consultations throughout the day. Consultations were therefore assumed to always be rate limiting in the main model runs.

It was not possible to determine whether the files and vital stages were rate limiting in the eight clinics on the day of data collection, due to the large amounts of missing data. Whether a stage is rate limiting or not may also vary over the course of a day. For instance, the files stage may potentially be rate limiting at the start of the clinic day only. Which stages are rate limiting is also to some extent a function of staff allocation. Blockages at files and vitals in particular can be alleviated, through assigning additional staff to those stages. That may not be possible for consultation stages however, where more specific staff skills may be required. For these reasons, we simulated four scheduling scenarios, with both files and vitals simulated as rate limiting, with neither simulated as rate limiting, and with only one simulated as rate limiting.

#### 1.6.1 Scheduling mechanism – rate limiting stages

When the files stage is set to be rate limiting in the model, then the gap between each attendee and the attendee after them (*gap\_files*) is kept the same as it is in the attendee input file. The files stage has a variable, *files\_status*, that tracks whether there is somebody currently at the stage ('busy'), or whether there is not ('free'). At the start of the model run, *files\_status* is set to free.

When *files\_status* is set to free, then the next attendee to arrive at the clinic (i.e. finish the preceding stage) immediately starts the files stage, setting *files\_status* to 'busy'. When they finish the files stage, after a gap of *duration\_files*, then the attendee at the start of the queue for files immediately starts the files stage, and removes themself from the files queue. If there are no attendees in the queue, then *files\_status* is set to free.

On arriving at the clinic, if *files\_status* is set to busy, attendees add themselves to the end of the files queue.

The scheduling mechanism works in the same way for the vitals and consultation stages, with attendees adding themselves to the queue for the stage after finishing the files and vitals stages respectively.

#### 1.6.2 Scheduling mechanism – non-rate limiting stages

When the files stage is set to be not rate limiting, then the gap between arrival (the preceding stage) and files, *gap\_files*, is kept the same as it is in the attendee input file. Upon arriving at the clinic, each attendee schedules their arrival at files, to occur after a gap of *gap\_files*.

The scheduling mechanism works in the same way for the vitals and consultation stages, with the preceding stages being files and vitals respectively.

#### 1.6.3 Attendee waiting areas

In the model, between arrival and files, between files and vitals, and between vitals and consultation, attendees wait in *files\_queue\_location*, *vitals\_queue\_location*, and *cons\_queue\_location* respectively.

#### 1.6.3.1 Queue management intervention

The exception to this is when the queue management intervention is simulated. The intervention is described more fully below, but briefly, it is assumed in the intervention that a maximum of only  $n_1$ ,  $n_2$ , and  $n_3$  attendees are allowed to wait inside the clinic before each of files, vitals, and consultations respectively, and that the rest wait in a single outdoor waiting area.

Upon arriving the clinic, simulated attendees check how many attendees are currently waiting inside the clinic for the files stage. If it is less than  $n_1$ , then they wait in *files\_queue\_location*. If it is greater or equal to  $n_1$ , then they wait in the outdoor waiting area, and add themselves to the end of a queue.

Each time a attendee reaches files, the length of the queue is checked. If it is greater than zero, then the first attendee in the queue changes their location to *files\_queue\_location*, and the attendee is removed from the queue.

The process is the same for vitals and consultations.

#### 1.7 Individual characteristics

Individuals in the model are classed as either children (aged <16 years) or adults (aged 16 years or over).

An individual's probability of having pulmonary TB at the time of their clinic visit (*prob\_infectious*) is set equal to *prob\_infectious\_adult* if they are an adult, and *prob\_infectious\_child* if they are a child.

An individual's breath volume rate (Ls<sup>-1</sup>) (*breathe\_rate*) is set equal to *breath\_rate\_adult* if they are an adult, and *breath\_rate\_child* if they are a child.

Individuals in the model wear masks with probability *prob\_wear\_mask*. This is set to zero in the baseline scenario, and in scenarios where no mask wearing intervention is simulated. Each individual has parameters *own\_mask\_reduction\_out* and *own\_mask\_reduction\_in*, which determine any reduction in the rate that they exhale or inhale quanta respectively, that is attributable to the fact they are wearing a mask. They parameters are set to zero if the individual is not wearing a mask, and to *mask\_reduction\_out* and *mask\_reduction\_in* respectively if the individual is wearing a mask.

#### 1.8 Room characteristics

Each room has a room volume, room\_volume, estimated from empirical data.

Each room has a rate of air change per hour (ACH), *air\_change\_rate\_h*, which is converted into a rate of air change per time step, *air\_change\_rate\_ts*.

For interventions that had no effect on ventilation rates, the same ventilation rates were used for each run for each paired baseline and intervention model run.

See section 'Intervention scenarios' for details of how *air\_change\_rate\_h* was estimated in intervention scenarios that altered ventilation rates.

The number of adults not wearing masks, children not wearing masks, adults wearing masks, and children wearing masks present in each room were tracked by the parameters

count\_adults\_no\_mask, count\_children\_no\_mask, count\_adults\_mask, and count\_children\_mask
respectively.

#### 1.9 Infection risk

Each simulated individual tracks the number of quanta in a room that were produced by themself (*own\_quanta\_in\_room*). This parameter is reset to zero each time an individual changes rooms. Each time step, it is updated using EQ1.

own\_quanta\_in\_room = (own\_quanta\_in\_room[t-1] \* (1 - (air\_change\_rate\_ts)) + EQ1
prob infectious \* quanta rate ts \* own mask reduction out)

The overall number of quanta in the room over time is tracked using equation EQ2

quanta\_in\_room = quanta\_in\_room[t-1] \* (1 - air\_change\_rate\_ts) EQ2

- + count\_adults\_no\_mask \* prop\_infectious\_adult \* quanta\_rate\_ts
- + count\_children\_no\_mask \* prop\_infectious\_child \* quanta\_rate\_ts
- + count\_adults\_mask \* prop\_infectious\_adult \* quanta\_rate\_ts \* mask\_reduction\_out
- + count\_children\_mask \* prop\_infectious\_child \* quanta\_rate\_ts \* mask\_reduction\_out

#### Finally, the risk to each individual each time step is calculated using EQ3

current\_risk = (1 - exp(- (quanta\_in\_room - own\_quanta\_in\_room) \* breath\_rate \* EQ3
own\_mask\_reduction\_in / room\_volume))

Overall infection risk was calculated as the sum of infection risk for all simulated individuals each time step, over all time they spent in clinic waiting areas

#### 1.10 Intervention scenarios

#### 1.10.1 Opening windows and doors

Empirical data were available from 20 experiments, where air change rates were estimated in the same room on the same day, both with the doors and windows in a typical in-use configuration ('usual conditions'), and with the doors and windows fully open ('max conditions'). For each of these, the ratio of the air change rate in max conditions compared to usual conditions was estimated. An exponential distribution was fitted to these estimated ratios (Figure 2), and simulated ratios in each room were sampled from the distribution for each model run. Estimated ratios were roughly similar

between the data (mean 4.8, median 2.7, IQR 1.4-4.3) and the modelled distribution (mean 3.7, median 2.7, IQR 1.3-5.5).

In the simulated intervention, it is assumed that all doors and windows are kept open at all times.



Figure S2. Empirical data on relative change in air changes per hour (ACH) with doors and windows fully open, compared to windows and doors in their typical configurations; and the distribution used to generate the changes in ACH values in the model

#### 1.10.2 Simple clinic retrofits

Retrofits are changes to the building to improve ventilation rates. This could include installing lattice brickwork or whirlybird fans. Due to the large amount of variation between clinic spaces in the types of building retrofits that would be suitable, and the lack of sufficient data on the effects of the retrofits on ventilation and air change rates in different types of spaces, we do not model specific retrofits or packages of retrofits. Instead, we simulate an undefined package of retrofits that are sufficient to increase air changes per hour to a minimum of 12 in all rooms, chosen in line with WHO guidelines<sup>67</sup>. This is implemented in the model through increasing *air\_change\_rate\_h* to 12 in all rooms and model runs where the sampled air change rate per hour is below 12.

#### 1.10.3 UVGI systems

We assume in this intervention that appropriate and well maintained ultraviolet germicidal irradiation (UVGI) systems are installed in all indoor clinic waiting areas.

Empirical data from studies of transmission to guinea pigs suggest that UVGI reduces the rate of transmission by 80% (95% CI 64%-88%)<sup>8</sup>, equivalent to a ventilation rate of 24 ACH (95% CI 9.9-62)<sup>8</sup>. This is implemented in the model through an additional quanta clearance rate, simulated in the same way as clearance through ventilation. The value of the additional quanta clearance rate is sampled for each waiting area and model run from a split normal distribution with mean 24 and 95% CI 9.9-62%.

#### 1.10.4 Surgical masks wearing by clinic attendees

Based on discussions with health care workers and professionals active in the management of health services in the two provinces we worked in, as well as review of qualitative data collected, we determined that a scenario where 70% of attendees wear surgical masks 90% of the time was plausible. This is implemented in the model as 63% of attendees wearing masks 100% of the time, with the attendees who wear the masks chosen at random each model run.

The relative reduction in the quanta production rate for each mask-wearing attendee each run is assumed to be the same, and the reduction is sampled for each model run from a split normal distribution with mean 75% and 95% CI 56-85%<sup>9</sup>.

We assume that masks have no effect on risk of infection for the person wearing the mask<sup>10</sup>.

#### 1.10.5 Increased CCMDD coverage

South Africa's Central Chronic Medicine Dispensing and Distribution (CCMDD) programme is designed to allow patients with stable chronic health conditions to collect their medicines from convenient locations, such as local pharmacies<sup>11</sup>. This means that they do not need to queue at clinics unnecessarily. The purpose of this intervention is to increase the coverage of CCMDD and

similar programmes for eligible patients on ART, and to ensure that pick-up points do not require patients to queue at clinics.

In simulating the intervention, we focus on ART patients only, as they make up a large proportion of patients attending for non-tuberculosis related chronic care (399/493, 81%, in the empirical datasets), and because few data were available on patients with other chronic conditions such as diabetes.

Visit reason was collected from all attendees visiting the clinics on the data collection days, with 'Chronic care: HIV/ART' being one of the reported reasons. We assume that some of the clinic visits with 'Chronic care: HIV/ART' being listed as the main visit reason would not be needed with the increased implementation of CCMDD. We therefore remove a proportion, *p*, of those attendees from the model.

In Western Cape clinics, there was an error during data collection, with the majority of patients who attended for HIV/ART related reasons having their main visit reason recorded as 'Acute care: minor problems'<sup>12</sup>. The correct proportions of adult male and female patients attending for HIV/ART related reasons were therefore estimated for Western Cape clinics from the proportions in the KwaZulu-Natal clinics, adjusted for the lower prevalence of HIV and ART coverage in Western Cape<sup>13</sup>. Adult Western Cape 'Acute care: minor problems' patients were then assigned at random, for each clinic and model run, to have attended for HIV/ART related reasons, to reach the desired proportion of male and female patients attending for HIV/ART related care.

2.8% of attendees report their visit reason as attending on behalf of somebody else. We assume that a proportion, *p*, of those visits would also need not occur under a scaled up CCMDD intervention.
For 69/120 (59%) people who reported their visit reason as accompanying an adult, and 72/179
(40%) people who reported their visit reason as accompanying a child, the visit reason of the person that they were accompanying could be determined. For accompanying people for whom the visit

reason of the person they were accompanying could not be determined, they were randomly assigned to be accompanying an HIV/ART patient each model run, with probability equal to the proportions where it could be determined, by clinic and whether they were accompanying an adult or a child. A proportion, *p*, of the visits of people assigned to accompanying someone attending the clinic for HIV/ART care were assumed not to have been needed under the intervention scenario.

The proportion, *p*, was determined using data from a social contacts survey of 1704 adults living in the catchment areas of two clinics in KwaZulu-Natal<sup>14</sup>. Respondents were asked to report the number of times that they had attended a clinic (for their own health) in the past six months. Self-reported HIV-positive people (of who 480/493 (97%) reported being on ART), reported a mean of 8.8 clinic visits per year, compared to 4.1 by HIV-/unknown. That is, an excess of 4.1 (95% CI 3.6-4.5) visits per year, controlling for age and sex, which we attribute to ART appointments. We assume that 92% (95% CI 84-95%) of people could have their ART appointments reduced to once every 6 months (the estimated proportion of people on ART who were virally suppressed 2019<sup>13</sup>), and that the remaining 8% of people need monthly ART appointments. This gives us a 31% reduction (IQR 22-34%) in HIV/ART care visits. For each clinic and model run, the number of excess visits and proportion of ART patients who are virally supressed are sampled from the relevant normal distributions, and *p* is calculated.

We implicitly assume that CCMDD pickup either occurs at a location away from the clinic; or requires patients to spend a negligible amount of time inside the clinic, without having any effect on the delays for other patients.

Ethical approval for the social contacts survey was granted by the Biomedical Research Ethics Committee (REC) of the University of KwaZulu-Natal (UKZN) (BE662/17) and the London School of Hygiene & Tropical Medicine (14640).

#### 1.10.6 Queue management system and outside waiting areas

Empirical data show that clinic waiting areas are often crowded, and that in many clinics attendees wait in unsuitable areas such as corridors<sup>12</sup>. Conversations with clinic staff suggested that this is partly due to patient concerns that if they wait in other areas, they may not hear their name being called, and may miss their turn. This intervention therefore combines a large, covered outdoor waiting area with a queue management system, such as numbered tickets or an electronic tracking system.

We assume in the model that only the next  $n_1$ ,  $n_2$ , and  $n_3$  attendees due to be seen at files, vitals, or for consultations respectively are allowed to wait inside the clinic. At smaller clinics, with fewer than 300 attendees on the day of data collection,  $n_1$ =5,  $n_2$ =5, and  $n_3$ =10. At larger clinics,  $n_1$ =10,  $n_2$ =10, and  $n_3$ =20. Once allowed inside the clinic, attendees are assumed to wait in the same location for each stage as they wait in the baseline scenario.

The volume of the outdoor waiting area is assumed to be equal to the sum of the volume of the existing clinic waiting areas. The ACH is the outdoor waiting area is drawn from a uniform distribution between 52 and 70 ACH for each clinic and model run<sup>15</sup>

#### 1.10.7 Appointment systems

In this intervention, we simulate an appointment system to reduce clinic overcrowding, through spacing out the arrival times of patients. As date-time appointment systems were already in place in some form in the Western Cape clinics on the day that the attendee data were collected, we only model the appointment intervention in the KwaZulu-Natal clinics.

We assume that appointments are given in 10-minute slots (i.e. a patient could be assigned 10:00 or 10:10, but not 10:05), between 9am and 1.50pm, and that patients arrive between 0-10 minutes before their appointment (sampled from a uniform distribution for each attendee). Once arrived at the clinic, simulated attendees are seen by clinic staff as soon as capacity allows, even if it is before

their appointment time. Arrival times are not changed for attendees who are not assigned appointments, and they enter the simulated queues at the time that they arrive at the clinic. Patients were assumed to be acute patients if their main reported visit reason was 'Acute care: minor problems' or 'Acute care: 24-hour emergency unit', and chronic otherwise. As with the CCMDD intervention, a proportion of patients at Western Cape clinics whose visit reason was recorded as 'Acute care: minor problems' was assumed to have visited for HIV/ART care – i.e. chronic care. In the model, appointments are given to all adult chronic patients. The first N acute patients are assumed to be seen the same day, as well as any children aged <16 years. The remaining adult acute patients are given appointments.

N is calculated for each clinic and model run by multiplying the total number of attendees counted on the day of data collection by the proportion of the total daily clinic time (length of time set aside for drop-in acute patients only plus the length of time that the clinic assigns appointments) that is set aside to see patients without appointments in the morning. N is then multiplied by a number drawn from a random uniform distribution between 0.75 and 1.25 for each clinic and model run, to reflect day-to-day fluctuations in the numbers of patients.

For 69/120 (59%) people who reported their visit reason as accompanying an adult, and 72/179 (40%) people who reported their visit reason as accompanying a child, the visit reason of the person that they were accompanying could be determined. For accompanying people for whom the visit reason of the person they were accompanying could not be determined, they were randomly assigned to be accompanying an acute or chronic patient each model run, with probability equal to the proportions where it could be determined, by clinic and accompanying adult or child. Accompanying people were given appointments or seen the same day based on the visit reason of the person they were accompanying.

It is assumed that there is no risk of transmission to or from attendees while they are receiving their appointment slots, reflecting the fact that many appointments could be arranged on a prior visit or

by telephone, and that the remaining appointments could be arranged quickly in a well ventilated or covered outdoor location, with the attendees rapidly leaving the clinic after receiving their appointment.

In the appointment system intervention, when the files stage in considered to be rate limiting (see section 'Movement through clinics'), the gap between attendees at files is reduced by 50%. This is done to incorporate a plausible reduction in the mean time taken to find files that might be achieved by pre-retrieval of files for patients with appointments.

## 1.11 Input parameter values

Parameter	Scenario	Description	Value	Source
prob_infectious_adult	All	Proportion of adults visiting the clinic that have pulmonary TB	0.010	Clinic prevalence survey <sup>4</sup>
prob_infectious_child	All	Proportion of children visiting the clinic that have pulmonary TB	0.00016	Clinic prevalence survey <sup>4</sup> , adjusting for lower proportion of smear+ disease in children <sup>2</sup> , and lower incidence of disease <sup>3</sup>
quanta_rate_hour	All	Rate of quanta production per hour for individuals with pulmonary TB	1.25	Andrews <i>et al</i> (2014) <sup>5</sup>
breath_rate_adult	All	Breath volume rate of adults (Ih <sup>-1</sup> )	480	Rudnick and Milton (2003) <sup>16</sup>
breath_rate_child	All	Breath volume rate of children (lh <sup>-1</sup> )	288	Rudnick and Milton (2003) <sup>16</sup> , adjusting for lower breathe volume in children <sup>17</sup>

quanta_rate_ts	All	Time step for updating	10	NA
		quanta and infection risk		
		estimates (seconds)		
min_ACH	Retrofits	Minimum air changes per	12	WHO guidelines <sup>67</sup>
		hour		
mask_reduction_out	Masks	Relative rate of quanta	0.25 (0.15-0.44)	Dharmadhikari <i>et al</i> (2012) <sup>9</sup>
		exhalation in individuals		
		with pulmonary TB who		
		wear a mask compared to		
		those who don't		
mask_reduction_in	Masks	Relative rate of quanta	1	MacIntyre (2015) <sup>10</sup>
		inhalation in individuals		
		without pulmonary TB who		
		wear a mask compared to		
		those who don't		
prob_wear_mask	Masks	Proportion of attendees	0.9 * 0.7 = 0.63	Expert opinion
		who wear a surgical mask		
UVGI_rate	UVGI	Rate of quanta clearance	24 ACH (95% CI 9.9-61.7)	Mphaphlele (2015) <sup>8</sup>
		due to UVGI, given in units		
		of the equivalent air		
		changes per hour		
	1		1	

files_indoor_number	Queue management	Number of attendees	Clinics 2, 8, 9, 12: 5;	Expert opinion
		allowed to wait inside the	Clinics 1, 5, 6, 11: 10	
		clinic for the files step		
vitals_indoor_number	Queue management	Number of attendees	Clinics 2, 8, 9, 12: 5;	Expert opinion
		allowed to wait inside the	Clinics 1, 5, 6, 11: 10	
		clinic for the files step		
consultation_indoor_number	Queue management	Number of attendees	Clinics 2, 8, 9, 12: 5;	Expert opinion
		allowed to wait inside the	Clinics 1, 5, 6, 11: 10	
		clinic for the files step		
outdoor_waiting_area_ACH	Queue management	Air changes per hour (ACH)	52-70	Escombe <i>et al</i> <sup>15</sup>
		in the outdoor waiting area		
excess_visits_ART	CCMDD	Number of excess clinic	4.1 (95% Cl 3.6-4.5)	Empirical social contact
		visits per year for people on		data <sup>14</sup>
		ART, compared to people		
		not on ART		
prop_viral_supressed	CCMDD	Proportion of patients on	92% (95% CI 84-95%)	AIDSinfo <sup>18</sup>
		ART who are virally		
		supressed		

## 2 Supplemental results

#### 2.1 Sensitivity analysis

Simulating consultations as a non-rate limiting stage reduced the estimated reduction in the rate of transmission to 15% (IQR 8.7-23%) in the CCMDD scale-up intervention, and 24% (IQR 13-47%) in the appointments intervention (Figure S3). It had no effects on the estimates for any other intervention.



Figure S3. Estimated reduction in the rate of *Mycobacterium tuberculosis* transmission to attendees in clinics, by province and intervention, when consultations are included in the model as a non-rate limiting stage. The central line indicates the median, the box range the interquartile range (IQR), the whiskers the most extreme value within 1.5 \* IQR from the box, and the points outlying values. In the queue management intervention in KwaZulu-Natal, 1% of points were below -50%, with a minimum of -162%. In the appointments intervention in KwaZulu-Natal, 0.28% of points were below -50%, with a minimum of -150%. These points are not shown on the graph. The appointment system intervention was not modelling in Western Cape, due to the presence of existing appointment systems. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.

#### 2.2 Intervention impact by clinic

100% Reduction in rate of transmission to patients Clinic **亡** 1 2 0% 5 6 8 9 11 -100% 12 UVGI Windows Retrofits . Masks CCMDD Appointments Queue & doors management Intervention

Figure S4 shows the effect of the interventions on the rate of transmission to attendees by clinic.

**Figure S4. Estimated reduction in the rate of** *Mycobacterium tuberculosis* transmission to **attendees in clinics, by clinic and intervention.** The central line indicates the median, the box range the interquartile range (IQR), the whiskers the most extreme value within 1.5 \* IQR from the box, and the points outlying values. The appointment system intervention was not modelling in Western Cape, due to the presence of existing appointment systems. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



#### 2.3 Attendee numbers and rate of transmission over time

Figure S5. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 2. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine

#### Dispensing and Distribution.



Figure S6. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 5. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



Figure S7. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 6. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



Figure S8. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 8. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



Figure S9. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 9. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on patient numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



Figure S10. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 11. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.



Figure S11. Number of attendees in the clinic over time in the baseline, appointments, and CCMDD interventions, and the mean rate of transmission to each attendee in the clinic over time in all scenarios, for clinic 12. The black line shows the median result, the dark red band the interquartile range, and the light red band the 95% plausible range. For interventions where a plot of the number of attendees over time is not shown, the intervention has no effect on attendee numbers. Transmission rates are relative to the highest transmission rate in any scenario at any point in time. UVGI stands for ultraviolet germicidal irradiation, and CCMDD for Central Chronic Medicine Dispensing and Distribution.

#### 2.4 Median clinic visit durations



**Figure S12. Median attendee times in clinic, by clinic and intervention.** The boxplots show the distribution of the median attendee time in the clinic for each model run (i.e. not the duration of time spent in the clinic by each attendee). The central line indicates the median across model runs, the box ranges the interquartile range (IQR), the whiskers the most extreme value within 1.5 \* IQR from the box, and the points outlying values. CCMDD for Central Chronic Medicine Dispensing and Distribution.

# **3** Supplemental acknowledgements

Name	Institution/s	Role
Siphokazi Adonisi	UCT	Research Assistant
Kathy Baisley	LSHTM; AHRI	Co-investigator
Peter Beckwith	LSHTM; UCT	Research fellow
Fiammetta Bozzani	LSHTM	Co-investigator
Amy Burdzik	UCT	Occupational health
Adrienne Burrough	LSHTM	Project Manager
Nkosingiphile Buthelezi	AHRI	Research Assistant
Xolile Buthelezi	AHRI	Diagnostic Lab Manager
Ruvimbo Chigwanda	UCT	Administration

The extended Umoya omuhle team, institutions, and roles (listed alphabetically by surname)

Christopher ColvinUCTCoinvestigatorPIP CRAsAHRCinic research AssistantsNjabulo DayiAHRResearch Data ManagerKarina DiaconuGMUCo-investigatorSiphephelo DiaminiAHRResearch AssistantRaveshni DurgiahAHRIResearch AssistantRaveshni DurgiahAHRIGrants officeAnita EdwardsGMUAdministratorJennifer FalconerQMUAdministratorPatrick GabelaAHRIHead: Scientific SupportJennifer SalconerQMUAdministratorPatrick GabelaAHRIHead: Research Data CoordinatorDickana GaretaAHRIHead: Research SaistantWarthu GawukebaUCTResearch AssistantWarthu GawukebaUCTResearch AssistantBarashni GovenderUKZNAdministrationIndira GovenderUSTM; AHRICo-investigatorMighann GreggLSEResearch AssistantAlson GrantUSTM; AHRICo-investigatorMeghann GreggLSEResearch AssistantSashin HarilallAHRICo-investigatorKobus HerbstAHRICo-investigatorSuzane KeyUCTResearch AssistantSuzane KeyUCTResearch AssistantSuzane KeyUCTResearch AssistantSuzane KeyUCTResearch AssistantMandia KhozaAHRICo-investigatorNovi KhumaloAHRICo-investigatorNori KhumaloAHRICo-investi	Name	Institution/s	Role
PIP CRASAHRIClinic research AssistantsNjabulo DayiAHRIResearch Data ManagerNinder DeolLSHTMMathematical modellerKarina DiaconuQMUCo-investigatorSiphephelo DlaminiAHRIResearch AssistantRaveshni DurgiahAHRIGrants officeAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantJennifer FalconerQMUMatinistratorDickman GaretaAHRIClinical Research Data CoordinatorDickman GaretaAHRIClinical Research Data CoordinatorDickman GaretaJENTIK, SHARIResearch AssistantBavashni GovenderUKTResearch AssistantIndira GovenderUSTAdministrationMighan GreggISEResearch AssistantSashin HarilallISFResearch AssistantSashin HarilallUCTResearch AssistantSashin HarilallUCTResearch AssistantSashin HarilallUCTResearch AssistantSashin HarilallUCTResearch AssistantArans KardJHRICo-investigatorArans KardAHRICo-investigatorArans KardAHRICo-investigatorArans KardJHRICo-investigatorSonaid KabiahUCTResearch AssistantArans KardJHRICo-investigatorArans KardAHRICo-investigatorArans KardAHRICo-investigatorArans KardAHRI<	Christopher Colvin	UCT	Co-investigator
Njabulo DayiAHRIResearch Data ManagerArminder DeolLSHTMMuthematical modellerKarina DiaconuQMQCo-investigatorSiphephelo DlaminiAHRINursing ManagerYutu DaminiAHRIResearch AssistantRaveshni DurgiahAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantIennifer FalconerQMUMarinistratorPatrick GabelaAHRIHead: Scientific SupportDickman GaretaAHRIHead: Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorAlison GrantLSFResearch AssistantAlison GrantLSFResearch AssistantKobus HerbstAHRIGrants officeKobus HerbstAHRICo-investigatorKobus HerbstUCTResearch AssistantKalonUCTResearch AssistantKalonUCT <td>PIP CRAs</td> <td>AHRI</td> <td>Clinic research Assistants</td>	PIP CRAs	AHRI	Clinic research Assistants
Arminder DeolLSHTMMathematical modellerKarina DiaconuQMUCo-investigatorSiphephelo DlaminiAHRINursing ManagerYutu DlaminiAHRIResearch AssistantRaveshni DurgiahAHRIResearch AssistantAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUAdministratorPatrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantBarriet GildonAHRI, UCLResearch AssistantBarriet GildonAHRI, UCLResearch AssistantBarriet GildonAHRI, UCLResearch AssistantBaroshni GovenderUSTNY, AHRICo-investigatorMeghan GreggLSEResearch fellowEmmerencia GumedeAHRIGrants officeSashni HarilallAHRIGrants officeSashni HarilallAHRIResearch AssistantSashni AratilalUCTResearch AssistantSashni AratilalAHRICo-investigatorSashni AratilalAHRICo-investigatorSashni AratilalAHRICo-investigatorSashni AtagianUCTResearch AssistantSashni AtagianUCTCo-investigatorSashni AtagianAHRICo-investigatorSashni AtagianAHRICo-investigatorSashni AtagianAHRICo-investigatorSashni AtagianAHRICo-investigator <t< td=""><td>Njabulo Dayi</td><td>AHRI</td><td>Research Data Manager</td></t<>	Njabulo Dayi	AHRI	Research Data Manager
Karina DiaconuQMUCo-investigatorSiphepho DlaminiAHRIMursing ManagerYutu DlaminiAHRIResearch AssistantRaveshni DurgiahAHRIGrants officeAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantKitty FlynnQMUResearch AssistantDickman GaretaAHRIClinical Research Data CoordinatorDickman GaretaAHRIClinical Research Data ManagementAwethu GawulekapaUCTResearch AssistantBavashni GovenderUSTMY, AHRICo-investigatorIdira GovenderLSTMY, AHRIPrincipal investigatorAlison GrantLSEResearch fellowSashin HaritalAHRIGrants officeSashin HaritalHARIGrants officeKobus HerbstAHRIGrants officeKobus HerbstLGTResearch AssistantSashin HaritalHARIGrants officeTamia JansenUCTResearch AssistantSuzank KeyUCTOcturul IstagatorMandla KhozaHARIClinic Research AssistantSuzank KeyUCTOcturul IstagatorNandla KhozaHARIClinic Research AssistantNata LassenUKZNResearch AssistantNata LassenGMUCo-investigatorMarina KealAHRIClinic Research AssistantNata LassenGARIClinic Research AssistantNata KalonUCTOcturul IstagatorNata Khanyile<	Arminder Deol	LSHTM	Mathematical modeller
Siphephelo DlaminiAHRINursing ManagerYutu DaminiAHRIResearch AssistantRaveshni DurgiahAHRIGrants officeAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantKitty FlynnQMUAdministratorPatrick GabelaAHRIHead: Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantDickman GaretaLSTMY; AHRICo-investigatorIdira GovenderUSTM; AHRICo-investigatorAlison GrantLSTM; AHRIResearch AssistantAlison GrantLSEResearch AssistantSashin HarilallAHRICenirvestigatorKobus HerbstAHRIChrier StatonSashin HarilallChrift Information OfficerTamia JansenUCTResearch AssistantSeonaid kabiahUCTResearch AssistantSurane KeyUCTOccupational nealthJarana KaalAHRICo-investigatorMandla KhozaAHRIClinic Research AssistantNazi KhumaloAHRICo-investigatorMandla KhozaAHRICo-investigatorSurane KeyUCTOccupational nealthNazi KhumaloAHRIClinic Research AssistantNazi KhumaloAHRIClinic Research AssistantNazi KhumaloAHRIClinic Research AssistantNazi KhumaloAHRIClinic Research AssistantNa	Karina Diaconu	QMU	Co-investigator
Yutu DlaminiAHRIResearch AssistantRaveshni DurgiahAHRIGrants officeAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantRatty FlynonQMUResearch AssistantPatrick GabelaAHRIClinical Research Data CoordinatorDickma GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantHarriet GildonAHRI, UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorMeghan GreggLSResearch AssistantBaron GreggUSTResearch AssistantSashin HarilallAHRIResearch AssistantSashin HarilallUCTResearch AssistantSashin HarilallUCTResearch AssistantSonaid KabiahUCTResearch AssistantSuano KaratUKZNResearch AssistantSuzano KaratUKZNResearch AssistantSuzano KayUCTCo-investigatorMandla KhozaAHRIComunicationsNazi KhumaloHARIComunicationsNazi KhumaloHARIComunicationsSuzano KeyUKZNResearch AssistantNaci KhumaloHARICorp-incipal investigatorNondumiso KumaloHARIClinic Research AssistantNorduriso KumaloHARIClinic Research AssistantNorduriso KumaloHARIClinic Research Assistant	Siphephelo Dlamini	AHRI	Nursing Manager
Raveshni DurgiahAHRIGrants officeAnita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantPatrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantBavashni GovenderUZZNAdministrationIndira GovenderUSTNAdministrationIndira GovenderUSTNAdministrationMeghan GreggLSEResearch AssistantEmmerencia GumedeAHRICo-investigatorSashni GaunedAHRIGrants officeKobus HerbstAHRIGrants officeSashni HarilallAHRIResearch AssistantSashni HarilallUCTResearch AssistantSashni HarilallUCTResearch AssistantSatom KaratUCTResearch AssistantSuzane KeyUCTOccupational healthSuzane KeyUCZNCo-investigatorMandla KhozaAHRICommunicationsSuzane KeyUCZNResearch AssistantNozi KhumaloAHRICo-investigatorNodumiso KumaloAHRICo-investigatorNodumiso KumaloAHRICo-investigatorNoduthula Lushaba (deceased)UZZNAdministrationNoduthuso KumaloAHRIResearch AssistantNoduthuso KumaloAHRICo-investigatorNoduthuso KumaloAHRICo-investigatorNoduthuso KumaloA	Yutu Dlamini	AHRI	Research Assistant
Anita EdwardsAHRIHead: Scientific SupportJennifer FalconerQMUResearch AssistantKitty FlynnQMUAdministratorPatrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantHarriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderUSTN; AHRICo-investigatorAlison GrantLSHTN; AHRICo-investigatorMeghann GreggLSEResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIGrants officeSound KabiahUCTResearch AssistantSound KabiahUCTResearch AssistantSeonaid KabiahUCTResearch AssistantSuzane KeyUCTCocinvestigatorXuana KaratLSHTM; AHRICo-investigatorXuana KeapUCTOccupational healthZuana KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNodumiso KumaloAHRIClinic Research AssistantNodumiso KumaloAHRI	Raveshni Durgiah	AHRI	Grants office
lennifer FalconerQMUResearch AssistantKitty FlynnQMUAdministratorPatrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research AssistantMartin GawulekapaUCTResearch AssistantHarriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderUKZNAdministrationAlison GrantLSHTM; AHRICo-investigatorMeghann GreggLSEResearch AssistantSashin HarilallAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIGrants officeSobaid KabiahUCTResearch AssistantSeonaid KabiahUCTResearch AssistantSuranne KeyUCTCo-investigatorAranna KratLSHTMCo-investigatorArana KaratUCTResearch AssistantSuzanne KeyUCTOccupational healthZaran KhanyileUKZNResearch AssistantNozi KhumaloAHRICommunicationsSuzanne KeyUCTOccupational healthZilethie KhumaloAHRIResearch AssistantNozi KhumaloAHRIResearch AssistantSizen Kasearch AssistantClinic Research AssistantSizen KeyUCTCo-principal investigatorNotak KhanyileAHRIResearch AssistantSizen Kasearch AssistantClinic Research AssistantSizen KeyUKZN	Anita Edwards	AHRI	Head: Scientific Support
Kitty FlynnQMUAdministratorPatrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantHarriet GilddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorMeghann GreggLSEResearch AssistantEmmerencia GumedeAHRIResearch AssistantSashin HarllAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonal KablahUCTResearch AssistantArant KardLSHTMCo-investigatorHannah KealUCTResearch AssistantSuzanne KeyUCTCo-investigatorAuron KaratLSHTMCo-investigatorSuzanne KeyUCTOccupational healthZaran KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNodumiso KumaloAHRIResearch AssistantNordinkiso Lubaba (deceased)UKZNResearch AssistantNordinkiso KumaloAHRIClinic Research AssistantNordinkiso LubabaAHRIClinic Research AssistantSithembios LubuhiAHRIClinic Research AssistantNondumiso KumaloA	Jennifer Falconer	QMU	Research Assistant
Patrick GabelaAHRIClinical Research Data CoordinatorDickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantHarriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorMeghann GreggLSEResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIGrants officeKobus HerbstAHRIChiromation OfficerTamia JansenUCTResearch AssistantSoonaid KablahUCTResearch AssistantSoonaid KablahUCTResearch AssistantSuzanne KeyUCTCo-investigatorAaron KaratLSHTMCo-investigatorSuzanne KeyUCTOccupational healthMandla KhozaAHRICommunicationsMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNokuthua Lushaba (deceased)UKZNAdministrationNokuthua Lushaba (deceased)UKZNAdministrationNokuthua Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIClinic Research AssistantSithembiso LuthuliAHRIClinic Research AssistantSithembiso L	Kitty Flynn	QMU	Administrator
Dickman GaretaAHRIHead: Research Data ManagementAwethu GawulekapaUCTResearch AssistantHarriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderISHTM; AHRICo-investigatorAlison GrantISHTM; AHRIResearch fellowMeghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashi HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerSashi HarilallUCTResearch AssistantSonaid KabiahUCTResearch AssistantSonaid KabiahUCTResearch AssistantVortasResearch AssistantIdriss KallonUCTCo-investigatorAaron KaratLSHTMCo-investigatorSuzana KeyUCTOccupational healthSuzana KeyUCTOccupational healthMandla KhozaAHRIClinic Research AssistantNazi KhumaloAHRIResearch AssistantNazi KhumaloAHRIClinic Research AssistantNazi KhumaloAHRIClinic Research AssistantNokuthula Lushaba (deceased)MIRIResearch AssistantNokuthula Lushaba (deceased)INFNResearch AssistantNokuthula Lushaba (deceased)UCXAdministrationNokuthula Lushaba (deceased)USCo-investigatorNokuthula Lushaba (deceased)USCo-investigatorNokuthula Lushaba (deceased)U	Patrick Gabela	AHRI	Clinical Research Data Coordinator
Awethu GawulekapaUCTResearch AssistantHarriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorAlison GrantLSHTM; AHRIResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonald KabiahUCTResearch AssistantIdriss KallonUCTResearch AssistantAaron KaratLSHTMCo-investigatorManda KkelAHRICommunicationsSuzanne KeyUCTOccupational healthJanshangoHARICommunicationsSuzanne KayUKZNResearch AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNodukinso KumaloHARICorputingal investigatorNondumiso KumaloHARIClinic Research AssistantNord KhumaloAHRIClinic Research AssistantNord KhumaloHARIEgidemiologistNord KumaloHARIEgidemiologistNohuthula Lushaba (deceased)UKZNAdministrationNokuthula Lushaba (deceased)IKRIResearch AssistantSithembiso LuthuliAHRIClinic Research AssistantSithembiso LuthuliAHRIClinic Research AssistantSithembiso LuthuliAHRI<	Dickman Gareta	AHRI	Head: Research Data Management
Harriet GliddonAHRI; UCLResearch AssistantBavashni GovenderUKZNAdministrationIndira GovenderLSHTN; AHRICo-investigatorAlison GrantLSHTN; AHRIPrincipal investigatorMeghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilalAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTResearch AssistantAaron KaratLSHTMCo-investigatorManda KealUKZNResearch AssistantSuzane KeyUCTOccupational healthZiama KhanyileUKZNResearch AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNodukinso KumaloAHRIClinic Research AssistantNodukinso KumaloAHRIEpidemiologistNohuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantAlaley MacGregorIDS <td>Awethu Gawulekapa</td> <td>UCT</td> <td>Research Assistant</td>	Awethu Gawulekapa	UCT	Research Assistant
Bavashni GovenderUKZNAdministrationIndira GovenderLSHTM; AHRICo-investigatorAlison GrantLSHTM; AHRIPrincipal investigatorMeghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIChief Information OfficerTamia JansenUCTResearch AssistantSoonaid KabiahUCTResearch AssistantIdriss KallonUCTResearch AssistantSaron KaratLSHTMCo-investigatorAaron KaratUTPost-doctoral researcherAaron KaratUTCo-investigatorSuzanne KeyUCTCoupational healthSuzanne KayUKZNResearch AssistantSuzanne KeyUKZNResearch AssistantSidelik KhumaloAHRICinic Research AssistantNozi KhumaloAHRICo-investigatorNozi KhumaloAHRIResearch AssistantStrina KielmannQMUCo-principal investigatorNoduthula Lushaba (deceased)UKZNAdministrationNoduthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRICo-investigatorSithembiso LuthuliAHRICo-investigatorSithembiso LuthuliAHRICo-investigatorSithembiso LuthuliAHRICo-investigatorSithembiso LuthuliAHRICo-investigatorSithembiso LuthuliAHRICo-investigator <td>Harriet Gliddon</td> <td>AHRI; UCL</td> <td>Research Assistant</td>	Harriet Gliddon	AHRI; UCL	Research Assistant
Indira GovenderLSHTM; AHRICo-investigatorAlison GrantLSHTM; AHRIPrincipal investigatorMeghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRIComunicationsSuzane KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantNotici KhumaloAHRICoinic Research AssistantNodumiso KumaloAHRICoinic Research AssistantKarina KielmannQMUCo-principal investigatorNordumiso KumaloAHRIEidemiologistNordumiso KumaloAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRICoinic Research AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch Assistant <td< td=""><td>Bavashni Govender</td><td>UKZN</td><td>Administration</td></td<>	Bavashni Govender	UKZN	Administration
Alison GrantLSHTM; AHRIPrincipal investigatorMeghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorManda KealULTOccupational healthSuzane KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRICinic Research AssistantNozi KhumaloAHRICorprincipal investigatorXiethia KielmannQMUCo-principal investigatorNondumiso KumaloAHRIEpidemiologistNondumiso KumaloAHRIClinic Research AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRICo-investigatorNonhalna MadughahJHRIClinic Research AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRICo-investigatorNohalnaha MadughahJUCTAdministrationAhrikoResearch AssistantSithemba MabuyakhuluAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIResearch AssistantAngle MacingerorIDSCo-investigator <td>Indira Govender</td> <td>LSHTM; AHRI</td> <td>Co-investigator</td>	Indira Govender	LSHTM; AHRI	Co-investigator
Meghann GreggLSEResearch fellowEmmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzane KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMadla KhozaAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNot KhumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Alison Grant	LSHTM; AHRI	Principal investigator
Emmerencia GumedeAHRIResearch AssistantSashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTPost-doctoral researcherIdriss KallonUCTPost-doctoral researcherAron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRICo-principal investigatorNot KhumaloAHRICo-principal investigatorNonduniso KumaloAHRICo-principal investigatorNonduniso KumaloAHRIClinic Research AssistantNohuhula Lushaba (deceased)UZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantAngley MacGregorIDSCo-investigatorNohlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationAphiwe MakalimaAHRIResearch AssistantSifundesihle MalembeAHRIResearch AssistantGordirey ManuelUCTAdministrationSifundesihle MalembeAHRIResearch AssistantGordirey ManuelUCTAdministration	Meghann Gregg	LSE	Research fellow
Sashin HarilallAHRIGrants officeKobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRIClinic Research AssistantNozi KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIResearch AssistantAhlyley MacGregorIDSCo-investigatorAphiwe MakalimaUCTAdministrationAphiwe MakalimaAHRIResearch AssistantAphiwe MakalimaAHRIResearch AssistantGordrey ManuelUCTAdministrationSifundesihe MalembeAHRIResearch Assistant	Emmerencia Gumede	AHRI	Research Assistant
Kobus HerbstAHRIChief Information OfficerTamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRICo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNokuthula Lushaba (deceased)UKZNAdministrationSithembias LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihe MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Sashin Harilall	AHRI	Grants office
Tamia JansenUCTResearch AssistantSeonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRICo-principal investigatorNothumaloAHRICo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantSithembiso LuthuliAHRIResearch AssistantSithembiso LuthuliAHRIClinic Research AssistantSintehmba MabuyakhuluAHRIClinic Research AssistantAhley MacGregorIDSCo-investigatorAphiwe MakalimaUCTAdministrationAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Kobus Herbst	AHRI	Chief Information Officer
Seonaid KabiahUCTResearch AssistantIdriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNodumiso KumaloAHRIEipidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSintehemba MabuyakhuluAHRIClinic Research AssistantAngley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Tamia Jansen	UCT	Research Assistant
Idriss KallonUCTPost-doctoral researcherAaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSintemba MabuyakhuluAHRICloinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Seonaid Kabiah	UCT	Research Assistant
Aaron KaratLSHTMCo-investigatorHannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Idriss Kallon	UCT	Post-doctoral researcher
Hannah KealAHRICommunicationsSuzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Aaron Karat	LSHTM	Co-investigator
Suzanne KeyUCTOccupational healthZama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNondumiso KumaloAHRIClinic Research AssistantNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Hannah Keal	AHRI	Communications
Zama KhanyileUKZNResearch AssistantMandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationSifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Suzanne Key	UCT	Occupational health
Mandla KhozaAHRIClinic Research AssistantNozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationSifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Zama Khanyile	UKZN	Research Assistant
Nozi KhumaloAHRISystems EngineerZilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeUCTTransport	Mandla Khoza	AHRI	Clinic Research Assistant
Zilethile KhumaloAHRIResearch AssistantKarina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeUCTTransport	Nozi Khumalo	AHRI	Systems Engineer
Karina KielmannQMUCo-principal investigatorNondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeUCTTransport	Zilethile Khumalo	AHRI	Research Assistant
Nondumiso KumaloAHRIClinic Research AssistantRichard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeUCTTransport	Karina Kielmann	QMU	Co-principal investigator
Richard LessellsAHRIEpidemiologistNokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Nondumiso Kumalo	AHRI	Clinic Research Assistant
Nokuthula Lushaba (deceased)UKZNAdministrationSithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Richard Lessells	AHRI	Epidemiologist
Sithembiso LuthuliAHRIResearch AssistantSinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Nokuthula Lushaba (deceased)	UKZN	Administration
Sinethemba MabuyakhuluAHRIClinic Research AssistantHayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Sithembiso Luthuli	AHRI	Research Assistant
Hayley MacGregorIDSCo-investigatorNonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Sinethemba Mabuyakhulu	AHRI	Clinic Research Assistant
Nonhlanhla MadlophaAHRIResearch AssistantAphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Hayley MacGregor	IDS	Co-investigator
Aphiwe MakalimaUCTAdministrationTacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Nonhlanhla Madlopha	AHRI	Research Assistant
Tacha MalazaAHRIPIP CRASifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Aphiwe Makalima	UCT	Administration
Sifundesihle MalembeAHRIResearch AssistantGodfrey ManuelUCTTransport	Tacha Malaza	AHRI	PIP CRA
Godfrey Manuel UCT Transport	Sifundesihle Malembe	AHRI	Research Assistant
	Godfrey Manuel	UCT	Transport

Name	Institution/s	Role
Nonhlanhla Maphumulo	UKZN	Administration
Precious Mathenjwa	UCT	Research Assistant
Sanele Mbuyazi	AHRI	PIP CRA
Nicky McCreesh	LSHTM	Co-investigator
Claire McLellan	QMU	Administrator
Simphiwe Mdluli	AHRI	PIP CRA
Thabile Mkhize	AHRI	Transport
Duduzile Mkhwanazi	AHRI	Research Assistant
Zinhle Mkhwanazi	AHRI	Research Assistant
Zodwa Mkhwanazi	AHRI	Research Assistant
Anathi Mngxekeza	UCT	Research Assistant
Tshwaraganang Modise	AHRI	Research Data
Sashen Moodley	AHRI	Microbiology Laboratory Supervisor
Samantha Moyo	UCT	Research Assistant
Silindile Mthembu	AHRI	Clinic Research Assistant
Nozipho Mthethwa	AHRI	Research Assistant
Siphesihle Mthethwa	AHRI	Procurement Coordinator
Sphiwe Mthethwa	AHRI	Research Assistant
Sanele Mthiyane	AHRI	Research Assistant
Vanisha Munsamy	AHRI	Grants office
Sinead Murphy	UCT	Research Assistant
Thomas Murray	AHRI	Research assistant
Senzile Myeni	AHRI	PIP CRA
Tevania Naidoo	AHRI	Procurement
Nompilo Ndlela	AHRI	Research Assistant
Zama Ndlela	AHRI	PIP CRA
Thandekile Nene	AHRI	Research Assistant
Phumla Ngcobo	AHRI	Communications
Nzuzo Ntombela	AHRI	Research Data Systems Service Manager
Sabelo Ntuli	AHRI	GIS Coordinator
Nompumulelo Nyawo	AHRI	Human resources
Phumzile Nywagi	UCT	Research Assistant
Stephen Olivier	AHRI	Statistician
Justin Parkhurst	LSE	Co-investigator
Alex Pym	AHRI	Co-investigator
Yolanda Qeja	UCT	Research Assistant
Anand Ramnanan (deceased)	AHRI	Procurement
Sharmila Rugbeer	UKZN	Administration
Janet Seeley	LSHTM	Co-investigator
Aruna Sevakram	AHRI	Scientific support
Sizwe Sikhakane	AHRI	Transport
Zizile Sikhosana	AHRI	Somkhele Laboratory Supervisor
Theresa Smit	AHRI	Head: Diagnostic Research
Thandeka Smith	UKZN	Research Assistant

Name	Institution/s	Role
Naomi Stewart	LSHTM	Communications
Alison Swartz	UCT	Co-investigator
Amy Thomas	LSHTM	Communications
Siphosethu Titise	UCT	Research Assistant
Anna Vassall	LSHTM	Co-investigator
Marlise Venter	AHRI	Facilities Administrator
Anna Voce	UKZN	Co-investigator
Richard White	LSHTM	Co-investigator
Tom Yates	Imperial	Co-investigator
Precious Zulu	AHRI	Administration
Gimenne Zwama	QMU	Research Fellow

AHRI: Africa Health Research Institute; IDS: Institute of Development Studies; LSE: London School of Economics and Political Science; LSHTM: London School of Hygiene & Tropical Medicine; QMU: Queen Margaret University; UCT: University of Cape Town; UKZN: University of KwaZulu-Natal;

## 4 References

- 1. Deol A, Beckwith P, Yates TA, et al. Estimating ventilation rates in rooms with varying occupancy levels: relevance for reducing transmission risk of airborne pathogens. *PLoS One* 2021;16(6):e0253096.
- Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, et al. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis 2016;16:282-82. doi: 10.1186/s12879-016-1617-9
- 3. World Health Organization. Global tuberculosis report 2019. Geneva, Switzerland: World Health Organization; 2019, 2019.
- 4. Govender I, Karat AS, Baisley K, et al. Prevalence of M. tuberculosis in sputum among clinic attendees compared with the surrounding community in rural South Africa: implications for finding the missing millions. 51st Union World Conference on Lung Health, 2020.
- 5. Andrews JR, Morrow C, Walensky RP, et al. Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. *Journal of Infectious Diseases* 2014;210(4):597-603.
- 6. World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update: World Health Organization 2019.
- 7. Chartier Y, Pessoa-Silva C. Natural ventilation for infection control in health-care settings: World Health Organization 2009.
- Mphaphlele M, Dharmadhikari AS, Jensen PA, et al. Institutional tuberculosis transmission. Controlled trial of upper room ultraviolet air disinfection: A basis for new dosing guidelines. *American Journal of Respiratory and Critical Care Medicine* 2015;192(4):477-84. doi: 10.1164/rccm.201501-00600C
- Dharmadhikari AS, Mphahlele M, Stoltz A, et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. 2012;185(10):1104-09.
- 10. MacIntyre CR, Chughtai AAJB. Facemasks for the prevention of infection in healthcare and community settings. 2015;350:h694.
- 11. Health Systems Trust. The CCMDD story, 2019.

- Karat AS, McCreesh N, Baisley K, et al. Waiting times, occupancy density, and patient flow in South African primary health clinics: implications for infection prevention and control. *MedRxiv* 2021;2021.07.21.21260806 doi: <u>https://doi.org/10.1101/2021.07.21.21260806</u>
   HST Indicator Tool. [Available from: https://indicators.hst.org.zo/ accessed 7/4/2020 2020]
- 13. HST Indicator Tool [Available from: <u>https://indicators.hst.org.za/</u> accessed 7/4/2020 2020.
- 14. McCreesh N, Dlamini V, Edwards A, et al. Impact of social distancing regulations and epidemic risk perception on social contact and SARS-CoV-2 transmission potential in rural South Africa: analysis of repeated cross-sectional surveys. *medRxiv* 2020;2020.12.01.20241877 doi: <u>https://doi.org/10.1101/2020.12.01.20241877</u>
- 15. Escombe AR, Ticona E, Chávez-Pérez V, et al. Improving natural ventilation in hospital waiting and consulting rooms to reduce nosocomial tuberculosis transmission risk in a low resource setting. *BMC infectious diseases* 2019;19(1):88.
- 16. Rudnick S, Milton DJIa. Risk of indoor airborne infection transmission estimated from carbon dioxide concentration. 2003;13(3):237-45.
- 17. Persily A, de Jonge LJIa. Carbon dioxide generation rates for building occupants. 2017;27(5):868-79.
- 18. UNAIDS. AIDSInfo [Available from: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo accessed 07/04/20.